


GRAHAM L. PATRICK



fifth edition

an introduction to

MEDICINAL CHEMISTRY

OXFORD

An Introduction to Medicinal Chemistry

This page intentionally left blank

An Introduction to

Medicinal Chemistry

FIFTH EDITION

Graham L. Patrick

OXFORD
UNIVERSITY PRESS

OXFORD
UNIVERSITY PRESS

Great Clarendon Street, Oxford, OX2 6DP,
United Kingdom

Oxford University Press is a department of the University of Oxford.
It furthers the University's objective of excellence in research, scholarship,
and education by publishing worldwide. Oxford is a registered trade mark of
Oxford University Press in the UK and in certain other countries

© Graham L. Patrick 2013

The moral rights of the author have been asserted

Second Edition copyright 2001

Third Edition copyright 2005

Fourth Edition copyright 2009

Impression: 1

All rights reserved. No part of this publication may be reproduced, stored in
a retrieval system, or transmitted, in any form or by any means, without the
prior permission in writing of Oxford University Press, or as expressly permitted
by law, by licence or under terms agreed with the appropriate reprographics
rights organization. Enquiries concerning reproduction outside the scope of the
above should be sent to the Rights Department, Oxford University Press, at the
address above

You must not circulate this work in any other form
and you must impose this same condition on any acquirer

British Library Cataloguing in Publication Data

Data available

ISBN 978-0-19-969739-7

Printed in Italy by

L.E.G.O. S.p.A.—Lavis TN

Links to third party websites are provided by Oxford in good faith and
for information only. Oxford disclaims any responsibility for the materials
contained in any third party website referenced in this work.

Preface

This text is aimed at undergraduates and postgraduates who have a basic grounding in chemistry and are studying a module or degree in medicinal chemistry. It attempts to convey, in a readable and interesting style, an understanding about drug design and the molecular mechanisms by which drugs act in the body. In so doing, it highlights the importance of medicinal chemistry in all our lives and the fascination of working in a field which overlaps the disciplines of chemistry, biochemistry, physiology, microbiology, cell biology, and pharmacology. Consequently, the book is of particular interest to students who might be considering a future career in the pharmaceutical industry.

New to this edition

Following the success of the first four editions, as well as useful feedback from readers, there has been some reorganization and updating of chapters, especially those in Part E.

Chapters have been modified, as appropriate, to reflect contemporary topics and teaching methods. This includes:

- new coverage of 99 drugs not featured in the previous edition;
- six new boxes, covering topics such ‘Cyclodextrins as drug scavengers’, ‘The structure-based drug design of crizotinib’, and ‘Designing a non-steroidal glucocorticoid agonist’;
- a new case study on steroidal anti-inflammatory agents;
- over 25 new sections, providing additional depth in subject areas including ‘Tethers and anchors’ and ‘Short-acting β -blockers’;
- additional end-of-chapter questions;
- current reference lists.

We have also made significant changes to the Online Resource Centre, adding 40 molecular modelling exercises and 16 web articles.

The structure of the book

Following the introductory chapter, the book is divided into five parts.

- Part A contains six chapters that cover the structure and function of important drug targets, such as recep-

tors, enzymes, and nucleic acids. Students with a strong background in biochemistry will already know this material, but may find these chapters a useful revision of the essential points.

- Part B covers pharmacodynamics in Chapters 7–10 and pharmacokinetics in Chapter 11. Pharmacodynamics is the study of how drugs interact with their molecular targets and the consequences of those interactions. Pharmacokinetics relates to the issues involved in a drug reaching its target in the first place.
- Part C covers the general principles and strategies involved in discovering and designing new drugs and developing them for the marketplace.
- Part D looks at particular ‘tools of the trade’ which are invaluable in drug design, i.e. QSAR, combinatorial synthesis, and computer-aided design.
- Part E covers a selection of specific topics within medicinal chemistry—antibacterial, antiviral and anticancer agents, cholinergics and anticholinesterases, adrenergics, opioid analgesics, and anti-ulcer agents. To some extent, those chapters reflect the changing emphasis in medicinal chemistry research. Antibacterial agents, cholinergics, adrenergics, and opioids have long histories and much of the early development of these drugs relied heavily on random variations of lead compounds on a trial and error basis. This approach was wasteful but it led to the recognition of various design strategies which could be used in a more rational approach to drug design. The development of the anti-ulcer drug cimetidine (Chapter 25) represents one of the early examples of the rational approach to medicinal chemistry. However, the real revolution in drug design resulted from giant advances made in molecular biology and genetics which have provided a detailed understanding of drug targets and how they function at the molecular level. This, allied to the use of molecular modelling and X-ray crystallography, has revolutionized drug design. The development of protease inhibitors as antiviral agents (Chapter 20), kinase inhibitors as anticancer agents (Chapter 21), and the statins as cholesterol-lowering agents (Case study 1) are prime examples of the modern approach.

G. L. P.
November 2012

About the book

The fifth edition of *An Introduction to Medicinal Chemistry* and its accompanying companion web site contains many learning features which will help you to understand this fascinating subject. This section explains how to get the most out of these.

Emboldened key words

Terminology is emboldened and defined in a glossary at the end of the book, helping you to become familiar with the language of medicinal chemistry.

Boxes

Boxes are used to present in-depth material and to explore how the concepts of medicinal chemistry are applied in practice.

Key points

Summaries at the end of major sections within chapters highlight and summarize key concepts and provide a basis for revision.

Questions

End-of-chapter questions allow you to test your understanding and apply concepts presented in the chapter.

Further reading

Selected references allow you to easily research those topics that are of particular interest to you.

Appendix

The appendix includes an index of drug names and their corresponding trade names, and an extensive glossary.

present in the drug can be important in forming intermolecular bonds with the target binding site. If they do so, they are called **binding groups**. However, the carbon skeleton of the drug also plays an important role in binding the drug to its target through van der Waals interactions. As far as the target binding site is concerned, it too contains functional groups and carbon skeletons which can form intermolecular bonds with 'visiting' drugs. The specific regions where this takes place are known as **binding regions**. The study of how drugs interact with their targets through binding interactions and produce a pharmacological effect is known as **pharmacodynamics**.

one or more of the following interactions, but not necessarily all of them.

1.3.1 Electrostatic or ionic bonds


An ionic or electrostatic bond is the strongest of the intermolecular bonds ($20\text{--}40\text{ kJ mol}^{-1}$) and takes place between groups that have opposite charges, such as a carboxylate ion and an aminium ion (Fig. 1.5). The strength of the interaction is inversely proportional to the distance between the two charged atoms and it is also dependent on the nature of the environment, being

BOX 3.1 The external control of enzymes by nitric oxide

The external control of enzymes is usually initiated by external chemical messengers which do not enter the cell. However, there is an exception to this. It has been discovered that cells can generate the gas **nitric oxide** by the reaction sequence shown in Fig. 1, catalysed by the enzyme **nitric oxide synthase**.

Because nitric oxide is a gas, it can diffuse easily through cell membranes into target cells. There, it activates enzymes

called **cyclases** to generate **cyclic GMP** from **GTP** (Fig. 2). Cyclic GMP then acts as a secondary messenger to influence other reactions within the cell. By this process, nitric oxide has an influence on a diverse range of physiological processes, including blood pressure, **neurotransmission**, and immunological defence mechanisms.



KEY POINTS

- Drugs act on molecular targets located in the cell membrane of cells or within the cells themselves.
- Drug targets are macromolecules that have a binding site into which the drug fits and binds.
- Most drugs bind to their targets by means of intermolecular bonds.
- Pharmacodynamics is the study of how drugs interact with their targets and produce a pharmacological effect.
- Electrostatic or ionic interactions occur between groups of

their pharmacological effect.

By chemical structure Many drugs which have a common skeleton are grouped together, for example penicillins, barbiturates, opiates, steroids, and catecholamines. In some cases, this is a useful classification as the biological activity and mechanism of action is the same for the structures involved, for example the antibiotic activity of penicillins. However, not all compounds with similar chemical structures have the same biological action. For example, steroids share a similar tetracyclic structure, but they have very different effects in the body. In this text, various groups of structurally-related drugs are discussed,

QUESTIONS

1. Enzymes can be used in organic synthesis. For example, the reduction of an aldehyde is carried out using aldehyde dehydrogenase. Unfortunately, this reaction requires the use of the cofactor NADH, which is expensive and is used up in the reaction. If ethanol is added to the reaction, only catalytic amounts of cofactor are required. Why?
2. Acetylcholine is the substrate for the enzyme acetylcholinesterase. Suggest what sort of binding

estradiol in the presence of the cofactor NADH. The initial rate data for the enzyme-catalysed reaction in the absence of an inhibitor is as follows:

Substrate concentration ($10^{-2}\text{ mol dm}^{-3}$) 5 10 25 50 100

Initial rate ($10^{-4}\text{ mol dm}^{-3}\text{ s}^{-1}$) 28.6 51.5 111 141 145

Create a Michaelis Menton plot and a Lineweaver-Burk plot. Use both plots to calculate the values of K_m and the

FURTHER READING

Broadwith, P. (2010) Enzymes do the twist. *Chemistry World*. Available at: <http://www.rsc.org/chemistryworld/News/2010/January/06011001.asp> (last accessed 14 June 2012).

Knowles, J. R. (1991) Enzyme catalysis: not different, just better. *Science* 350, 121–124.

Maryanoff, B. E. and Maryanoff, C. A. (1992) Some thoughts on enzyme inhibition and the quiescent affinity label concept. *Advances in Medicinal Chemistry* 1, 235–261.


Navia, M. A. and Murcko, M. A. (1992) Use of structural information in drug design. *Current Opinion in Structural Biology* 2, 202–216.

Teague, S. J. (2003) Implications of protein flexibility for drug discovery. *Nature Reviews Drug Discovery* 2, 527–541.

Appendix 1

Essential amino acids


NON POLAR
(hydrophobic)



About the Online Resource Centre

Online Resource Centres provide students and lecturers with ready-to-use teaching and learning resources. They are free of charge, designed to complement the textbook, and offer additional materials which are suited to electronic delivery.

You will find the material to accompany *An Introduction to Medicinal Chemistry* at: www.oxfordtextbooks.co.uk/orc/patrick5e/



Student resources

Rotatable 3D structures

Links to where you can view the structures from the book in interactive rotating form.

Web articles

Developments in the field since the book published and further information that you may find of interest.

Molecular modelling exercises

Develop your molecular modelling skills, using Wavefunction's *Spartan*TM software to answer the set questions. To answer all the questions, you will need the full version of *Spartan*, which is widely distributed at colleges and universities; check with your institution for access.

You will be able to answer a selection of the questions and familiarize yourself with the basics using *Spartan Student Edition*TM. Students can purchase this from store.wavefun.com/product_p/SpStudent.htm. Enter the promotional code OUPAIMC to receive 20% discount for students using *An Introduction to Medicinal Chemistry*. For questions or support for *Spartan*TM, visit www.wavefun.com.

Multiple choice questions

Test yourself on the topics covered in the text and receive instant feedback.

Lecturer resources

For registered adopters of the book

All these resources can be downloaded and are fully customizable, allowing them to be incorporated into your institution's existing virtual learning environment.

Test bank

A bank of multiple choice questions, which can be downloaded and customized for your teaching.

Answers

Answers to end-of-chapter questions.

Figures from the book

All of the figures from the textbook are available to download electronically for use in lectures and handouts.

PowerPoint slides

PowerPoint slides are provided to help teach selected topics from the book.

Acknowledgements

The author and Oxford University Press would like to thank the following people who have given advice on the various editions of this textbook:

Dr Lee Banting, School of Pharmacy and Biomedical Sciences, University of Portsmouth, UK

Dr Don Green, Department of Health and Human Sciences, London Metropolitan University, UK

Dr Mike Southern, Department of Chemistry, Trinity College, University of Dublin, Ireland

Dr Mikael Elofsson (Assistant Professor), Department of Chemistry, Umeå University, Sweden

Dr Ed Moret, Faculty of Pharmaceutical Sciences, Utrecht University, the Netherlands

Professor John Nielsen, Department of Natural Sciences, Royal Veterinary and Agricultural University, Denmark

Professor Henk Timmerman, Department of Medicinal Chemistry, Vrije Universiteit, the Netherlands

Professor Nouri Neamati, School of Pharmacy, University of Southern California, USA

Professor Kristina Luthman, Department of Chemistry, Gothenburg University, Sweden

Professor Taleb Altel, College of Pharmacy, University of Sarjah, United Arab Emirates

Professor Dirk Rijkers, Faculty of Pharmaceutical Sciences, Utrecht University, the Netherlands

Dr Sushama Dandekar, Department of Chemistry, University of North Texas, USA

Dr John Spencer, Department of Chemistry, University of Sussex, UK

Dr Angeline Kanagasooriam, School of Physical Sciences, University of Kent at Canterbury, UK

Dr A Ganesan, School of Chemistry, University of Southampton, UK

Dr Rachel Dickens, Department of Chemistry, University of Durham, UK

Dr Gerd Wagner, School of Chemical Sciences and Pharmacy, University of East Anglia, UK

Dr Colin Fishwick, School of Chemistry, University of Leeds, UK

Professor Paul O'Neil, Department of Chemistry, University of Liverpool, UK

Professor Trond Ulven, Department of Chemistry, University of Southern Denmark, Denmark

Professor Jennifer Powers, Department of Chemistry and Biochemistry, Kennesaw State University, USA

Professor Joanne Kehlbeck, Department of Chemistry, Union College, USA

Dr Robert Sinclair, Faculty of Pharmaceutical Sciences, University of British Columbia, Canada

Professor John Carran, Department of Chemistry, Queen's University, Canada

Professor Anne Johnson, Department of Chemistry and Biology, Ryerson University, Canada

Dr Jane Hanrahan, Faculty of Pharmacy, University of Sydney, Australia

Dr Ethel Forbes, School of Science, University of West of Scotland, UK

Dr Zoë Waller, School of Pharmacy, University of East Anglia, UK

Dr Susan Matthews, School of Pharmacy, University of East Anglia, UK

Professor Ulf Nilsson, Organic Chemistry, Lund University, Sweden

Dr Russell Pearson, School of Physical and Geographical Sciences, Keele University, UK

Dr Rachel Codd, Sydney Medical School, The University of Sydney, Australia

Dr Marcus Durrant, Department of Chemical and Forensic Sciences, Northumbria University, UK

Dr Alison Hill, College of Life and Environmental Sciences, University of Exeter, UK

Dr Connie Locher, School of Biomedical, Biomolecular and Chemical Sciences, University of Western Australia, Australia

Dr Angeline Kanagasooriam, School of Physical Sciences, University of Kent, UK

Jon Våbenø, Department of Pharmacy, University of Tromsø, Norway

The author would like to express his gratitude to Dr John Spencer of the University of Sussex for co-authoring Chapter 16, the preparation of several web articles, and for feedback during the preparation of this fifth edition. Much appreciation is owed to Nahoum Anthony and Dr Rachel Clark of the Strathclyde Institute for Pharmaceutical and Biomedical Sciences at the University of Strathclyde for their assistance with creating Figures 2.9; Box 8.2, Figures 1 and 3; and Figures 17.9, 17.44, 20.15, 20.22, 20.54, and 20.55 from pdb files, some of which were obtained from the RSCB Protein Data Bank. Dr James Keeler of the Department of Chemistry, University of Cambridge, kindly generated the molecular models that appear on the book's Online Resource Centre. Thanks also to Dr Stephen Bromidge of GlaxoSmithKline for permitting the description of his work on selective 5-HT_{2C} antagonists, and for providing many of the diagrams for that web article. Finally, many thanks to Cambridge Scientific, Oxford Molecular, and Tripos for their advice and assistance in the writing of Chapter 17.

Brief contents

List of boxes	xix		
Acronyms and abbreviations	xxi		
1 Drugs and drug targets: an overview	1		
PART A Drug targets			
2 Protein structure and function	17		
3 Enzymes: structure and function	30		
4 Receptors: structure and function	42		
5 Receptors and signal transduction	58		
6 Nucleic acids: structure and function	71		
PART B Pharmacodynamics and pharmacokinetics			
7 Enzymes as drug targets	87		
8 Receptors as drug targets	102		
9 Nucleic acids as drug targets	120		
10 Miscellaneous drug targets	135		
11 Pharmacokinetics and related topics	153		
■ Case study 1: Statins	178		
PART C Drug discovery, design, and development			
12 Drug discovery: finding a lead	189		
13 Drug design: optimizing target interactions	215		
14 Drug design: optimizing access to the target	248		
15 Getting the drug to market	274		
■ Case study 2: The design of angiotensin-converting enzyme (ACE) inhibitors	292		
■ Case study 3: Artemisinin and related antimalarial drugs	299		
■ Case study 4: The design of oxamniquine	305		
PART D Tools of the trade			
16 Combinatorial and parallel synthesis	313		
17 Computers in medicinal chemistry	337		
18 Quantitative structure–activity relationships (QSAR)	383		
■ Case study 5: Design of a thymidylate synthase inhibitor	407		
PART E Selected topics in medicinal chemistry			
19 Antibacterial agents	413		
20 Antiviral agents	468		
21 Anticancer agents	514		
22 Cholinergics, anticholinergics, and anticholinesterases	578		
23 Drugs acting on the adrenergic nervous system	609		
24 The opioid analgesics	632		
25 Anti-ulcer agents	659		
■ Case study 6: Steroidal anti-inflammatory agents	689		
■ Case Study 7: Current research into antidepressant agents	700		
Appendix 1 Essential amino acids	705		
Appendix 2 The standard genetic code	706		
Appendix 3 Statistical data for quantitative structure–activity relationships (QSAR)	707		
Appendix 4 The action of nerves	711		
Appendix 5 Microorganisms	715		
Appendix 6 Drugs and their trade names	717		
Appendix 7 Trade names and drugs	722		
Appendix 8 Hydrogen bonding interactions	728		
Appendix 9 Drug properties	730		
Glossary	741		
General further reading	761		
Index	763		

Contents

List of boxes	xix		
Acronyms and abbreviations	xxi		
1 Drugs and drug targets: an overview	1		
1.1 What is a drug?	1		
1.2 Drug targets	3		
1.2.1 Cell structure	3		
1.2.2 Drug targets at the molecular level	4		
1.3 Intermolecular bonding forces	5		
1.3.1 Electrostatic or ionic bonds	5		
1.3.2 Hydrogen bonds	6		
1.3.3 Van der Waals interactions	8		
1.3.4 Dipole–dipole and ion–dipole interactions	8		
1.3.5 Repulsive interactions	9		
1.3.6 The role of water and hydrophobic interactions	10		
1.4 Pharmacokinetic issues and medicines	11		
1.5 Classification of drugs	11		
1.6 Naming of drugs and medicines	12		
		3.4 Substrate binding at an active site	32
		3.5 The catalytic role of enzymes	32
		3.5.1 Binding interactions	32
		3.5.2 Acid/base catalysis	33
		3.5.3 Nucleophilic groups	34
		3.5.4 Cofactors	35
		3.5.5 Naming and classification of enzymes	35
		3.5.6 Genetic polymorphism and enzymes	35
		3.6 Regulation of enzymes	36
		3.7 Isozymes	39
		3.8 Enzyme kinetics	39
		3.8.1 The Michaelis-Menton equation	39
		3.8.2 Lineweaver-Burk plots	40
		4 Receptors: structure and function	42
		4.1 Role of the receptor	42
		4.2 Neurotransmitters and hormones	42
		4.3 Receptor types and subtypes	45
		4.4 Receptor activation	45
		4.5 How does the binding site change shape?	45
		4.6 Ion channel receptors	47
		4.6.1 General principles	47
		4.6.2 Structure	48
		4.6.3 Gating	49
		4.6.4 Ligand-gated and voltage-gated ion channels	49
		4.7 G-protein-coupled receptors	50
		4.7.1 General principles	50
		4.7.2 Structure	51
		4.7.3 The rhodopsin-like family of G-protein-coupled receptors	51
		4.7.4 Dimerization of G-coupled receptors	53
		4.8 Kinase-linked receptors	53
		4.8.1 General principles	53
		4.8.2 Structure of tyrosine kinase receptors	54
		4.8.3 Activation mechanism for tyrosine kinase receptors	54
		4.8.4 Tyrosine kinase-linked receptors	54
		4.9 Intracellular receptors	55
		4.10 Regulation of receptor activity	56
		4.11 Genetic polymorphism and receptors	56
		5 Receptors and signal transduction	58
		5.1 Signal transduction pathways for G-protein-coupled receptors	58
		5.1.1 Interaction of the receptor–ligand complex with G-proteins	58
		5.1.2 Signal transduction pathways involving the α -subunit	59
		5.2 Signal transduction involving G-proteins and adenylate cyclase	60
PART A Drug targets			
2 Protein structure and function	17		
2.1 The primary structure of proteins	17		
2.2 The secondary structure of proteins	18		
2.2.1 The α -helix	18		
2.2.2 The β -pleated sheet	18		
2.2.3 The β -turn	18		
2.3 The tertiary structure of proteins	19		
2.3.1 Covalent bonds—disulphide links	21		
2.3.2 Ionic or electrostatic bonds	21		
2.3.3 Hydrogen bonds	21		
2.3.4 Van der Waals and hydrophobic interactions	22		
2.3.5 Relative importance of bonding interactions	23		
2.3.6 Role of the planar peptide bond	23		
2.4 The quaternary structure of proteins	23		
2.5 Translation and post-translational modifications	25		
2.6 Proteomics	26		
2.7 Protein function	26		
2.7.1 Structural proteins	26		
2.7.2 Transport proteins	27		
2.7.3 Enzymes and receptors	27		
2.7.4 Miscellaneous proteins and protein–protein interactions	28		
3 Enzymes: structure and function	30		
3.1 Enzymes as catalysts	30		
3.2 How do enzymes catalyse reactions?	31		
3.3 The active site of an enzyme	31		

5.2.1	Activation of adenylate cyclase by the α_s -subunit	60	7.7.3	Enzyme inhibitors used against the body's own enzymes	95
5.2.2	Activation of protein kinase A	60	7.8	Enzyme kinetics	97
5.2.3	The G_i -protein	62	7.8.1	Lineweaver-Burk plots	97
5.2.4	General points about the signalling cascade involving cyclic AMP	62	7.8.2	Comparison of inhibitors	99
5.2.5	The role of the $\beta\gamma$ -dimer	63			
5.2.6	Phosphorylation	63			
5.3	Signal transduction involving G-proteins and phospholipase C	64	8	Receptors as drug targets	102
5.3.1	G-protein effect on phospholipase C	64	8.1	Introduction	102
5.3.2	Action of the secondary messenger: diacylglycerol	65	8.2	The design of agonists	102
5.3.3	Action of the secondary messenger: inositol triphosphate	65	8.2.1	Binding groups	102
5.3.4	Re-synthesis of phosphatidylinositol diphosphate	65	8.2.2	Position of the binding groups	104
5.4	Signal transduction involving kinase-linked receptors	66	8.2.3	Size and shape	105
5.4.1	Activation of signalling proteins and enzymes	66	8.2.4	Other design strategies	105
5.4.2	Small G-proteins	67	8.2.5	Pharmacodynamics and pharmacokinetics	105
5.4.3	Activation of guanylate cyclase by kinase receptors	68	8.2.6	Examples of agonists	106
			8.2.7	Allosteric modulators	106
			8.3	The design of antagonists	107
6	Nucleic acids: structure and function	71	8.3.1	Antagonists acting at the binding site	107
6.1	Structure of DNA	71	8.3.2	Antagonists acting out with the binding site	110
6.1.1	The primary structure of DNA	71	8.4	Partial agonists	111
6.1.2	The secondary structure of DNA	71	8.5	Inverse agonists	112
6.1.3	The tertiary structure of DNA	74	8.6	Desensitization and sensitization	112
6.1.4	Chromatins	76	8.7	Tolerance and dependence	114
6.1.5	Genetic polymorphism and personalized medicine	76	8.8	Receptor types and subtypes	114
6.2	Ribonucleic acid and protein synthesis	76	8.9	Affinity, efficacy, and potency	116
6.2.1	Structure of RNA	76	9	Nucleic acids as drug targets	120
6.2.2	Transcription and translation	77	9.1	Intercalating drugs acting on DNA	120
6.2.3	Small nuclear RNA	79	9.2	Topoisomerase poisons: non-intercalating	121
6.3	Genetic illnesses	79	9.3	Alkylating and metallating agents	123
6.4	Molecular biology and genetic engineering	81	9.3.1	Nitrogen mustards	124
			9.3.2	Nitrosoureas	124
			9.3.3	Busulfan	124
			9.3.4	Cisplatin	125
			9.3.5	Dacarbazine and procarbazine	126
			9.3.6	Mitomycin C	127
			9.4	Chain cutters	128
			9.5	Chain terminators	129
			9.6	Control of gene transcription	130
			9.7	Agents that act on RNA	131
			9.7.1	Agents that bind to ribosomes	131
			9.7.2	Antisense therapy	131
			10	Miscellaneous drug targets	135
			10.1	Transport proteins as drug targets	135
			10.2	Structural proteins as drug targets	135
			10.2.1	Viral structural proteins as drug targets	135
			10.2.2	Tubulin as a drug target	135
			10.3	Biosynthetic building blocks as drug targets	138
			10.4	Biosynthetic processes as drug targets: chain terminators	139
			10.5	Protein-protein interactions	139

PART B Pharmacodynamics and pharmacokinetics

7 Enzymes as drug targets 87

7.1	Inhibitors acting at the active site of an enzyme	87
7.1.1	Reversible inhibitors	87
7.1.2	Irreversible inhibitors	89
7.2	Inhibitors acting at allosteric binding sites	89
7.3	Uncompetitive and non-competitive inhibitors	90
7.4	Transition-state analogues: renin inhibitors	90
7.5	Suicide substrates	92
7.6	Isozyme selectivity of inhibitors	93
7.7	Medicinal uses of enzyme inhibitors	93
7.7.1	Enzyme inhibitors used against microorganisms	93
7.7.2	Enzyme inhibitors used against viruses	95

xii Contents

10.6	Lipids as drug targets	143	12.2	Choosing a drug target	189
10.6.1	‘Tunnelling molecules’	143	12.2.1	Drug targets	189
10.6.2	Ion carriers	146	12.2.2	Discovering drug targets	189
10.6.3	Tethers and anchors	147	12.2.3	Target specificity and selectivity between species	191
10.7	Carbohydrates as drug targets	148	12.2.4	Target specificity and selectivity within the body	191
10.7.1	Glycomics	148	12.2.5	Targeting drugs to specific organs and tissues	192
10.7.2	Antigens and antibodies	149	12.2.6	Pitfalls	192
10.7.3	Cyclodextrins	151	12.2.7	Multi-target drugs	193
11	Pharmacokinetics and related topics	153	12.3	Identifying a bioassay	195
11.1	The three phases of drug action	153	12.3.1	Choice of bioassay	195
11.2	A typical journey for an orally active drug	153	12.3.2	<i>In vitro</i> tests	195
11.3	Drug absorption	154	12.3.3	<i>In vivo</i> tests	195
11.4	Drug distribution	156	12.3.4	Test validity	196
11.4.1	Distribution around the blood supply	156	12.3.5	High-throughput screening	196
11.4.2	Distribution to tissues	156	12.3.6	Screening by nuclear magnetic resonance	197
11.4.3	Distribution to cells	156	12.3.7	Affinity screening	197
11.4.4	Other distribution factors	156	12.3.8	Surface plasmon resonance	197
11.4.5	Blood–brain barrier	156	12.3.9	Scintillation proximity assay	198
11.4.6	Placental barrier	157	12.3.10	Isothermal titration calorimetry	198
11.4.7	Drug–drug interactions	157	12.3.11	Virtual screening	198
11.5	Drug metabolism	157	12.4	Finding a lead compound	199
11.5.1	Phase I and phase II metabolism	158	12.4.1	Screening of natural products	199
11.5.2	Phase I transformations catalysed by cytochrome P450 enzymes	158	12.4.2	Medical folklore	202
11.5.3	Phase I transformations catalysed by flavin-containing monooxygenases	160	12.4.3	Screening synthetic compound ‘libraries’	202
11.5.4	Phase I transformations catalysed by other enzymes	160	12.4.4	Existing drugs	203
11.5.5	Phase II transformations	160	12.4.5	Starting from the natural ligand or modulator	204
11.5.6	Metabolic stability	163	12.4.6	Combinatorial and parallel synthesis	207
11.5.7	The first pass effect	167	12.4.7	Computer-aided design of lead compounds	207
11.6	Drug excretion	167	12.4.8	Serendipity and the prepared mind	207
11.7	Drug administration	168	12.4.9	Computerized searching of structural databases	209
11.7.1	Oral administration	169	12.4.10	Fragment-based lead discovery	209
11.7.2	Absorption through mucous membranes	169	12.4.11	Properties of lead compounds	211
11.7.3	Rectal administration	169	12.5	Isolation and purification	212
11.7.4	Topical administration	169	12.6	Structure determination	212
11.7.5	Inhalation	170	12.7	Herbal medicine	212
11.7.6	Injection	170	13	Drug design: optimizing target interactions	215
11.7.7	Implants	171	13.1	Structure–activity relationships	215
11.8	Drug dosing	171	13.1.1	Binding role of alcohols and phenols	216
11.8.1	Drug half-life	172	13.1.2	Binding role of aromatic rings	217
11.8.2	Steady state concentration	172	13.1.3	Binding role of alkenes	218
11.8.3	Drug tolerance	173	13.1.4	The binding role of ketones and aldehydes	218
11.8.4	Bioavailability	173	13.1.5	Binding role of amines	218
11.9	Formulation	173	13.1.6	Binding role of amides	219
11.10	Drug delivery	174	13.1.7	Binding role of quaternary ammonium salts	221
■	Case study 1: Statins	178	13.1.8	Binding role of carboxylic acids	221
			13.1.9	Binding role of esters	222
			13.1.10	Binding role of alkyl and aryl halides	222
			13.1.11	Binding role of thiols and ethers	223
			13.1.12	Binding role of other functional groups	223
			13.1.13	Binding role of alkyl groups and the carbon skeleton	223
			13.1.14	Binding role of heterocycles	223
			13.1.15	Isosteres	225

PART C Drug discovery, design, and development

12. Drug discovery: finding a lead 189

12.1	Choosing a disease	189
------	--------------------	-----

13.1.16	Testing procedures	226	14.6.1	Prodrugs to improve membrane permeability	259
13.1.17	SAR in drug optimization	226	14.6.2	Prodrugs to prolong drug activity	260
13.2	Identification of a pharmacophore	227	14.6.3	Prodrugs masking drug toxicity and side effects	261
13.3	Drug optimization: strategies in drug design	228	14.6.4	Prodrugs to lower water solubility	262
13.3.1	Variation of substituents	228	14.6.5	Prodrugs to improve water solubility	262
13.3.2	Extension of the structure	231	14.6.6	Prodrugs used in the targeting of drugs	263
13.3.3	Chain extension/contraction	231	14.6.7	Prodrugs to increase chemical stability	263
13.3.4	Ring expansion/contraction	231	14.6.8	Prodrugs activated by external influence (sleeping agents)	264
13.3.5	Ring variations	233	14.7	Drug alliances	264
13.3.6	Ring fusions	234	14.7.1	'Sentry' drugs	264
13.3.7	Isosteres and bioisosteres	234	14.7.2	Localizing a drug's area of activity	265
13.3.8	Simplification of the structure	236	14.7.3	Increasing absorption	265
13.3.9	Rigidification of the structure	239	14.8	Endogenous compounds as drugs	265
13.3.10	Conformational blockers	241	14.8.1	Neurotransmitters	265
13.3.11	Structure-based drug design and molecular modelling	241	14.8.2	Natural hormones, peptides, and proteins as drugs	266
13.3.12	Drug design by NMR spectroscopy	243	14.8.3	Antibodies as drugs	267
13.3.13	The elements of luck and inspiration	243	14.9	Peptides and peptidomimetics in drug design	268
13.3.14	Designing drugs to interact with more than one target	243	14.9.1	Peptidomimetics	268
14	Drug design: optimizing access to the target	248	14.9.2	Peptide drugs	270
14.1	Optimizing hydrophilic/hydrophobic properties	248	14.10	Oligonucleotides as drugs	271
14.1.1	Masking polar functional groups to decrease polarity	249	15	Getting the drug to market	274
14.1.2	Adding or removing polar functional groups to vary polarity	249	15.1	Preclinical and clinical trials	274
14.1.3	Varying hydrophobic substituents to vary polarity	249	15.1.1	Toxicity testing	274
14.1.4	Variation of <i>N</i> -alkyl substituents to vary pK_a	250	15.1.2	Drug metabolism studies	276
14.1.5	Variation of aromatic substituents to vary pK_a	250	15.1.3	Pharmacology, formulation, and stability tests	277
14.1.6	Bioisosteres for polar groups	250	15.1.4	Clinical trials	277
14.2	Making drugs more resistant to chemical and enzymatic degradation	251	15.2	Patenting and regulatory affairs	281
14.2.1	Steric shields	251	15.2.1	Patents	281
14.2.2	Electronic effects of bioisosteres	251	15.2.2	Regulatory affairs	283
14.2.3	Steric and electronic modifications	252	15.3	Chemical and process development	285
14.2.4	Metabolic blockers	252	15.3.1	Chemical development	285
14.2.5	Removal or replacement of susceptible metabolic groups	253	15.3.2	Process development	286
14.2.6	Group shifts	253	15.3.3	Choice of drug candidate	289
14.2.7	Ring variation and ring substituents	254	15.3.4	Natural products	289
14.3	Making drugs less resistant to drug metabolism	255	■	Case study 2: The design of angiotensin-converting enzyme (ACE) inhibitors	292
14.3.1	Introducing metabolically susceptible groups	255	■	Case study 3: Artemisinin and related antimalarial drugs	299
14.3.2	Self-destruct drugs	255	■	Case study 4: The design of oxamniquine	305
14.4	Targeting drugs	256	PART D Tools of the trade		
14.4.1	Targeting tumour cells: 'search and destroy' drugs	256	16	Combinatorial and parallel synthesis	313
14.4.2	Targeting gastrointestinal infections	257	16.1	Combinatorial and parallel synthesis in medicinal chemistry projects	313
14.4.3	Targeting peripheral regions rather than the central nervous system	257	16.2	Solid phase techniques	314
14.4.4	Targeting with membrane tethers	257	16.2.1	The solid support	314
14.5	Reducing toxicity	258	16.2.2	The anchor/linker	315
14.6	Prodrugs	258	16.2.3	Examples of solid phase syntheses	317

16.3	Planning and designing a compound library	318	17.11.1	X-ray crystallography	355
16.3.1	'Spider-like' scaffolds	318	17.11.2	Structural comparison of active compounds	355
16.3.2	Designing 'drug-like' molecules	318	17.11.3	Automatic identification of pharmacophores	355
16.3.3	Synthesis of scaffolds	319	17.12	Docking procedures	356
16.3.4	Substituent variation	319	17.12.1	Manual docking	356
16.3.5	Designing compound libraries for lead optimization	319	17.12.2	Automatic docking	357
16.3.6	Computer-designed libraries	320	17.12.3	Defining the molecular surface of a binding site	357
16.4	Testing for activity	321	17.12.4	Rigid docking by shape complementarity	358
16.4.1	High-throughput screening	321	17.12.5	The use of grids in docking programs	361
16.4.2	Screening 'on bead' or 'off bead'	321	17.12.6	Rigid docking by matching hydrogen bonding groups	361
16.5	Parallel synthesis	322	17.12.7	Rigid docking of flexible ligands: the FLOG program	361
16.5.1	Solid phase extraction	323	17.12.8	Docking of flexible ligands: anchor and grow programs	362
16.5.2	The use of resins in solution phase organic synthesis (SPOS)	324	17.12.9	Docking of flexible ligands: simulated annealing and genetic algorithms	366
16.5.3	Reagents attached to solid support: catch and release	324	17.13	Automated screening of databases for lead compounds	366
16.5.4	Microwave technology	325	17.14	Protein mapping	366
16.5.5	Microfluidics in parallel synthesis	325	17.14.1	Constructing a model protein: homology modelling	367
16.6	Combinatorial synthesis	328	17.14.2	Constructing a binding site: hypothetical pseudoreceptors	368
16.6.1	The mix and split method in combinatorial synthesis	328	17.15	<i>De novo</i> drug design	370
16.6.2	Structure determination of the active compound(s)	329	17.15.1	General principles of <i>de novo</i> drug design	370
16.6.3	Dynamic combinatorial synthesis	331	17.15.2	Automated <i>de novo</i> drug design	371
17	Computers in medicinal chemistry	337	17.16	Planning compound libraries	379
17.1	Molecular and quantum mechanics	337	17.17	Database handling	379
17.1.1	Molecular mechanics	337	18	Quantitative structure–activity relationships (QSAR)	383
17.1.2	Quantum mechanics	337	18.1	Graphs and equations	383
17.1.3	Choice of method	338	18.2	Physicochemical properties	384
17.2	Drawing chemical structures	338	18.2.1	Hydrophobicity	385
17.3	Three-dimensional structures	338	18.2.2	Electronic effects	388
17.4	Energy minimization	339	18.2.3	Steric factors	390
17.5	Viewing 3D molecules	339	18.2.4	Other physicochemical parameters	392
17.6	Molecular dimensions	341	18.3	Hansch equation	392
17.7	Molecular properties	341	18.4	The Craig plot	392
17.7.1	Partial charges	341	18.5	The Topliss scheme	394
17.7.2	Molecular electrostatic potentials	342	18.6	Bioisosteres	397
17.7.3	Molecular orbitals	343	18.7	The Free-Wilson approach	397
17.7.4	Spectroscopic transitions	343	18.8	Planning a QSAR study	397
17.7.5	The use of grids in measuring molecular properties	344	18.9	Case study	398
17.8	Conformational analysis	346	18.10	Three-dimensional QSAR	401
17.8.1	Local and global energy minima	346	18.10.1	Defining steric and electrostatic fields	401
17.8.2	Molecular dynamics	346	18.10.2	Relating shape and electronic distribution to biological activity	402
17.8.3	Stepwise bond rotation	347	18.10.3	Advantages of CoMFA over traditional QSAR	403
17.8.4	Monte Carlo and the Metropolis method	348			
17.8.5	Genetic and evolutionary algorithms	350			
17.9	Structure comparisons and overlays	351			
17.10	Identifying the active conformation	352			
17.10.1	X-ray crystallography	352			
17.10.2	Comparison of rigid and non-rigid ligands	353			
17.11	3D pharmacophore identification	354			

18.10.4	Potential problems of CoMFA	403	20	Antiviral agents	468
18.10.5	Other 3D QSAR methods	404	20.1	Viruses and viral diseases	468
18.10.6	Case study: inhibitors of tubulin polymerization	404	20.2	Structure of viruses	468
■	Case study 5: Design of a thymidylate synthase inhibitor	407	20.3	Life cycle of viruses	469
PART E Selected topics in medicinal chemistry					
19	Antibacterial agents	413	20.4	Vaccination	470
19.1	History of antibacterial agents	413	20.5	Antiviral drugs: general principles	471
19.2	The bacterial cell	415	20.6	Antiviral drugs used against DNA viruses	472
19.3	Mechanisms of antibacterial action	415	20.6.1	Inhibitors of viral DNA polymerase	472
19.4	Antibacterial agents which act against cell metabolism (antimetabolites)	416	20.6.2	Inhibitors of tubulin polymerization	474
19.4.1	Sulphonamides	416	20.6.3	Antisense therapy	475
19.4.2	Examples of other antimetabolites	420	20.7	Antiviral drugs acting against RNA viruses: HIV	476
19.5	Antibacterial agents which inhibit cell wall synthesis	421	20.7.1	Structure and life cycle of HIV	476
19.5.1	Penicillins	421	20.7.2	Antiviral therapy against HIV	477
19.5.2	Cephalosporins	436	20.7.3	Inhibitors of viral reverse transcriptase	478
19.5.3	Other β -lactam antibiotics	442	20.7.4	Protease inhibitors	480
19.5.4	β -Lactamase inhibitors	444	20.7.5	Inhibitors of other targets	493
19.5.5	Other drugs which act on bacterial cell wall biosynthesis	445	20.8	Antiviral drugs acting against RNA viruses: flu virus	496
19.6	Antibacterial agents which act on the plasma membrane structure	450	20.8.1	Structure and life cycle of the influenza virus	496
19.6.1	Valinomycin and gramicidin A	450	20.8.2	Ion channel disrupters: adamantanes	498
19.6.2	Polymyxin B	450	20.8.3	Neuraminidase inhibitors	498
19.6.3	Killer nanotubes	450	20.9	Antiviral drugs acting against RNA viruses: cold virus	507
19.6.4	Cyclic lipopeptides	451	20.10	Antiviral drugs acting against RNA viruses: hepatitis C	508
19.7	Antibacterial agents which impair protein synthesis: translation	452	20.11	Broad-spectrum antiviral agents	510
19.7.1	Aminoglycosides	452	20.11.1	Agents acting against cytidine triphosphate synthetase	510
19.7.2	Tetracyclines	454	20.11.2	Agents acting against S-adenosylhomocysteine hydrolase	510
19.7.3	Chloramphenicol	455	20.11.3	Ribavirin	510
19.7.4	Macrolides	455	20.11.4	Interferons	510
19.7.5	Lincosamides	456	20.11.5	Antibodies and ribozymes	511
19.7.6	Streptogramins	456	20.12	Bioterrorism and smallpox	511
19.7.7	Oxazolidinones	456	21	Anticancer agents	514
19.8	Agents that act on nucleic acid transcription and replication	457	21.1	Cancer: an introduction	514
19.8.1	Quinolones and fluoroquinolones	457	21.1.1	Definitions	514
19.8.2	Aminoacridines	459	21.1.2	Causes of cancer	514
19.8.3	Rifamycins	460	21.1.3	Genetic faults leading to cancer: proto-oncogenes and oncogenes	514
19.8.4	Nitroimidazoles and nitrofurantoin	460	21.1.4	Abnormal signalling pathways	515
19.8.5	Inhibitors of bacterial RNA polymerase	461	21.1.5	Insensitivity to growth-inhibitory signals	516
19.9	Miscellaneous agents	461	21.1.6	Abnormalities in cell cycle regulation	516
19.10	Drug resistance	462	21.1.7	Apoptosis and the p53 protein	517
19.10.1	Drug resistance by mutation	462	21.1.8	Telomeres	519
19.10.2	Drug resistance by genetic transfer	463	21.1.9	Angiogenesis	519
19.10.3	Other factors affecting drug resistance	463	21.1.10	Tissue invasion and metastasis	521
19.10.4	The way ahead	463	21.1.11	Treatment of cancer	521
			21.1.12	Resistance	523
			21.2	Drugs acting directly on nucleic acids	524

21.2.1	Intercalating agents	524	22 Cholinergics, anticholinergics, and anticholinesterases	578	
21.2.2	Non-intercalating agents which inhibit the action of topoisomerase enzymes on DNA	526	22.1	The peripheral nervous system	578
21.2.3	Alkylating and metallating agents	526	22.2	Motor nerves of the PNS	578
21.2.4	Chain cutters	529	22.2.1	The somatic motor nervous system	579
21.2.5	Antisense therapy	529	22.2.2	The autonomic motor nervous system	579
21.3	Drugs acting on enzymes: antimetabolites	531	22.2.3	The enteric system	580
21.3.1	Dihydrofolate reductase inhibitors	531	22.2.4	Defects in motor nerve transmission	580
21.3.2	Inhibitors of thymidylate synthase	532	22.3	The cholinergic system	580
21.3.3	Inhibitors of ribonucleotide reductase	534	22.3.1	The cholinergic signalling system	580
21.3.4	Inhibitors of adenosine deaminase	535	22.3.2	Presynaptic control systems	580
21.3.5	Inhibitors of DNA polymerases	535	22.3.3	Co-transmitters	581
21.3.6	Purine antagonists	536	22.4	Agonists at the cholinergic receptor	582
21.3.7	Inhibitors of poly ADP ribose polymerase	536	22.5	Acetylcholine: structure, structure–activity relationships, and receptor binding	583
21.4	Hormone-based therapies	536	22.6	The instability of acetylcholine	584
21.4.1	Glucocorticoids, estrogens, progestins, and androgens	537	22.7	Design of acetylcholine analogues	585
21.4.2	Luteinizing hormone-releasing hormone agonists	537	22.7.1	Steric shields	585
21.4.3	Anti-estrogens	538	22.7.2	Electronic effects	586
21.4.4	Anti-androgens	538	22.7.3	Combining steric and electronic effects	586
21.4.5	Aromatase inhibitors	538	22.8	Clinical uses for cholinergic agonists	586
21.5	Drugs acting on structural proteins	539	22.8.1	Muscarinic agonists	586
21.5.1	Agents which inhibit tubulin polymerization	540	22.8.2	Nicotinic agonists	586
21.5.2	Agents which inhibit tubulin depolymerization	542	22.9	Antagonists of the muscarinic cholinergic receptor	587
21.6	Inhibitors of signalling pathways	544	22.9.1	Actions and uses of muscarinic antagonists	587
21.6.1	Inhibition of farnesyl transferase and the Ras protein	544	22.9.2	Muscarinic antagonists	588
21.6.2	Protein kinase inhibitors	547	22.10	Antagonists of the nicotinic cholinergic receptor	590
21.7	Miscellaneous enzyme inhibitors	561	22.10.1	Applications of nicotinic antagonists	590
21.7.1	Matrix metalloproteinase inhibitors	561	22.10.2	Nicotinic antagonists	591
21.7.2	Proteasome inhibitors	563	22.11	Receptor structures	594
21.7.3	Histone deacetylase inhibitors	564	22.12	Anticholinesterases and acetylcholinesterase	595
21.7.4	Other enzyme targets	564	22.12.1	Effect of anticholinesterases	595
21.8	Miscellaneous anticancer agents	564	22.12.2	Structure of the acetylcholinesterase enzyme	595
21.8.1	Synthetic agents	565	22.12.3	The active site of acetylcholinesterase	596
21.8.2	Natural products	566	22.13	Anticholinesterase drugs	597
21.8.3	Protein therapy	566	22.13.1	Carbamates	598
21.8.4	Modulation of transcription factor–co-activator interactions	567	22.13.2	Organophosphorus compounds	600
21.9	Antibodies, antibody conjugates, and gene therapy	568	22.14	Pralidoxime: an organophosphate antidote	602
21.9.1	Monoclonal antibodies	568	22.15	Anticholinesterases as ‘smart drugs’	603
21.9.2	Antibody–drug conjugates	568	22.15.1	Acetylcholinesterase inhibitors	603
21.9.3	Antibody-directed enzyme prodrug therapy (ADEPT)	570	22.15.2	Dual-action agents acting on the acetylcholinesterase enzyme	604
21.9.4	Antibody-directed abzyme prodrug therapy (ADAPT)	572	22.15.3	Multi-targeted agents acting on the acetylcholinesterase enzyme and the muscarinic M ₂ receptor	606
21.9.5	Gene-directed enzyme prodrug therapy (GDEPT)	572	23 Drugs acting on the adrenergic nervous system	609	
21.9.6	Other forms of gene therapy	573	23.1	The adrenergic nervous system	609
21.10	Photodynamic therapy	573			

23.1.1	Peripheral nervous system	609	24.7	Agonists and antagonists	647
23.1.2	Central nervous system	609	24.8	Endogenous opioid peptides and opioids	649
23.2	Adrenergic receptors	609	24.8.1	Endogenous opioid peptides	649
23.2.1	Types of adrenergic receptor	609	24.8.2	Analogues of enkephalins and δ -selective opioids	650
23.2.2	Distribution of receptors	610	24.8.3	Binding theories for enkephalins	652
23.3	Endogenous agonists for the adrenergic receptors	611	24.8.4	Inhibitors of peptidases	653
23.4	Biosynthesis of catecholamines	611	24.8.5	Endogenous morphine	653
23.5	Metabolism of catecholamines	612	24.9	The future	653
23.6	Neurotransmission	612	24.9.1	The message–address concept	653
23.6.1	The neurotransmission process	612	24.9.2	Receptor dimers	654
23.6.2	Co-transmitters	612	24.9.3	Selective opioid agonists versus multi-targeted opioids	655
23.6.3	Presynaptic receptors and control	613	24.9.4	Peripheral-acting opioids	655
23.7	Drug targets	614	24.10	Case study: design of nalfurafine	655
23.8	The adrenergic binding site	614	25	Anti-ulcer agents	659
23.9	Structure–activity relationships	615	25.1	Peptic ulcers	659
23.9.1	Important binding groups on catecholamines	615	25.1.1	Definition	659
23.9.2	Selectivity for α - versus β -adrenoceptors	616	25.1.2	Causes	659
23.10	Adrenergic agonists	616	25.1.3	Treatment	659
23.10.1	General adrenergic agonists	616	25.1.4	Gastric acid release	659
23.10.2	α_1 -, α_2 -, β_1 -, and β_3 -Agonists	617	25.2	H ₂ antagonists	660
23.10.3	β_2 -Agonists and the treatment of asthma	618	25.2.1	Histamine and histamine receptors	661
23.11	Adrenergic receptor antagonists	620	25.2.2	Searching for a lead	662
23.11.1	General α -/ β -blockers	620	25.2.3	Developing the lead: a chelation bonding theory	665
23.11.2	α -Blockers	620	25.2.4	From partial agonist to antagonist: the development of burimamide	665
23.11.3	β -Blockers as cardiovascular drugs	621	25.2.5	Development of metiamide	667
23.12	Other drugs affecting adrenergic transmission	626	25.2.6	Development of cimetidine	670
23.12.1	Drugs that affect the biosynthesis of adrenergics	626	25.2.7	Cimetidine	671
23.12.2	Drugs inhibiting the uptake of noradrenaline into storage vesicles	627	25.2.8	Further studies of cimetidine analogues	673
23.12.3	Release of noradrenaline from storage vesicles	627	25.2.9	Further H ₂ antagonists	676
23.12.4	Reuptake inhibitors of noradrenaline into presynaptic neurons	627	25.2.10	Comparison of H ₁ and H ₂ antagonists	678
23.12.5	Inhibition of metabolic enzymes	629	25.2.11	H ₂ -receptors and H ₂ antagonists	679
24	The opioid analgesics	632	25.3	Proton pump inhibitors	679
24.1	History of opium	632	25.3.1	Parietal cells and the proton pump	679
24.2	The active principle: morphine	632	25.3.2	Proton pump inhibitors	680
24.2.1	Isolation of morphine	632	25.3.3	Mechanism of inhibition	681
24.2.2	Structure and properties	633	25.3.4	Metabolism of proton pump inhibitors	682
24.3	Structure–activity relationships	633	25.3.5	Design of omeprazole and esomeprazole	682
24.4	The molecular target for morphine: opioid receptors	635	25.3.6	Other proton pump inhibitors	684
24.5	Morphine: pharmacodynamics and pharmacokinetics	636	25.4	<i>Helicobacter pylori</i> and the use of antibacterial agents	685
24.6	Morphine analogues	638	25.4.1	Discovery of <i>Helicobacter pylori</i>	685
24.6.1	Variation of substituents	638	25.4.2	Treatment	685
24.6.2	Drug extension	638	25.5	Traditional and herbal medicines	687
24.6.3	Simplification or drug dissection	640	■	Case study 6: Steroidal anti-inflammatory agents	689
24.6.4	Rigidification	644	■	Case Study 7: Current research into antidepressant agents	700
			APPENDIX 1	Essential amino acids	705
			APPENDIX 2	The standard genetic code	706

xviii Contents

APPENDIX 3 Statistical data for quantitative structure–activity relationships (QSAR)	707	APPENDIX 8 Hydrogen bonding interactions	728
APPENDIX 4 The action of nerves	711	APPENDIX 9 Drug properties	730
APPENDIX 5 Microorganisms	715	GLOSSARY	741
APPENDIX 6 Drugs and their trade names	717	GENERAL FURTHER READING	761
APPENDIX 7 Trade names and drugs	722	INDEX	763

List of boxes

General interest		
3.1	The external control of enzymes by nitric oxide	38
7.1	A cure for antifreeze poisoning	88
7.2	Irreversible inhibition for the treatment of obesity	90
7.3	Suicide substrates	94
7.4	Designing drugs to be isozyme-selective	95
7.5	Action of toxins on enzymes	96
8.1	An unexpected agonist	106
8.2	Estradiol and the estrogen receptor	109
10.1	Antidepressant drugs acting on transport proteins	136
10.2	Targeting transcription factors: co-activator interactions	140
10.3	Cyclodextrins as drug scavengers	150
11.1	Metabolism of an antiviral agent	164
12.1	Recently discovered targets: the caspases	190
12.2	Pitfalls in choosing particular targets	192
12.3	Early tests for potential toxicity	193
12.4	Selective optimization of side activities (SOSA)	205
12.5	Natural ligands as lead compounds	206
12.6	Examples of serendipity	207
12.7	The use of NMR spectroscopy in finding lead compounds	209
12.8	Click chemistry <i>in situ</i>	211
13.1	Converting an enzyme substrate to an inhibitor by extension tactics	232
13.2	Simplification	237
13.3	Rigidification tactics in drug design	240
13.4	The structure-based drug design of crizotinib	242
14.1	The use of bioisosteres to increase absorption	251
14.2	Shortening the lifetime of a drug	256
14.3	Varying esters in prodrugs	260
14.4	Prodrugs masking toxicity and side effects	262
14.5	Prodrugs to improve water solubility	263
15.1	Drug metabolism studies and drug design	276
16.1	Examples of scaffolds	320
17.1	Energy minimizing apomorphine	340
17.2	Study of HOMO and LUMO orbitals	344
17.3	Finding conformations of cyclic structures by molecular dynamics	347
17.4	Identification of an active conformation	353
17.5	Constructing a receptor map	369
17.6	Designing a non-steroidal glucocorticoid agonist	378
18.1	Altering log <i>P</i> to remove central nervous system side effects	387
18.2	Insecticidal activity of diethyl phenyl phosphates	390
18.3	Hansch equation for a series of antimalarial compounds	393
19.1	Sulphonamide analogues with reduced toxicity	417
19.2	Treatment of intestinal infections	418
19.5	The isoxazolyl penicillins	432
19.7	Ampicillin prodrugs	434
19.20	Organoarsenicals as antiparasitic drugs	465
21.7	Development of a non-peptide farnesyl transferase inhibitor	547
21.10	Design of sorafenib	557
21.13	Gemtuzumab ozogamicin: an antibody–drug conjugate	571
22.1	Mosses play it smart	604
24.3	Opioids as anti-diarrhoeal agents	644
24.6	Design of naltrindole	651
Synthesis		
15.2	Synthesis of ebalzotan	287
15.3	Synthesis of ICI D7114	287
16.2	Dynamic combinatorial synthesis of vancomycin dimers	334
19.9	Synthesis of 3-methylated cephalosporins	439
19.17	Synthesis of ciprofloxacin	458
21.8	General synthesis of gefitinib and related analogues	550
21.9	General synthesis of imatinib and analogues	553
23.2	Synthesis of salbutamol	619
23.3	Synthesis of aryloxypropanolamines	623
24.2	Synthesis of <i>N</i> -alkylated morphine analogues	639
24.4	Synthesis of the orvinols	646
25.1	Synthesis of cimetidine	672
25.2	Synthesis of omeprazole and esomeprazole	686
CS2.1	Synthesis of captopril and enalaprilate	297
CS4.1	Synthesis of oxamniquine	310

xx List of boxes

Clinical correlation					
		20.2	Clinical aspects of antiviral drugs used against HIV	478	
19.3	Clinical properties of benzylpenicillin and phenoxymethylpenicillin	423	20.3	Clinical aspects of reverse transcriptase inhibitors	481
19.4	<i>Pseudomonas aeruginosa</i>	426	20.4	Clinical aspects of protease inhibitors (PIs)	493
19.6	Clinical aspects of β -lactamase-resistant penicillins	432	21.1	Clinical aspects of intercalating agents	525
19.8	Clinical aspects of broad-spectrum penicillins	435	21.2	Clinical aspects of non-intercalating agents inhibiting the action of topoisomerase enzymes on DNA	527
19.10	Clinical aspects of cephalosporins	442	21.3	Clinical aspects of alkylating and metallating agents	530
19.11	Clinical aspects of miscellaneous β -lactam antibiotics	443	21.4	Clinical aspects of antimetabolites	533
19.12	Clinical aspects of cycloserine, bacitracin, and vancomycin	451	21.5	Clinical aspects of hormone-based therapies	540
19.13	Clinical aspects of drugs acting on the plasma membrane	452	21.6	Clinical aspects of drugs acting on structural proteins	543
19.14	Clinical aspects of aminoglycosides	453	21.11	Clinical aspects of kinase inhibitors	559
19.15	Clinical aspects of tetracyclines and chloramphenicol	454	21.12	Clinical aspects of antibodies and antibody–drug conjugates	569
19.16	Clinical aspects of macrolides, lincosamides, streptogramins, and oxazolidinones	457	23.1	Clinical aspects of adrenergic agents	611
19.18	Clinical aspects of quinolones and fluoroquinolones	459	23.4	Clinical aspects of β -blockers	624
19.19	Clinical aspects of rifamycins and miscellaneous agents	462	24.1	Clinical aspects of morphine	633
20.1	Clinical aspects of viral DNA polymerase inhibitors	475	24.5	A comparison of opioids and their effects on opioid receptors	649
		CS3.1	Clinical properties of artemisinin and analogues	303	
		CS6.1	Clinical aspects of glucocorticoids	692	

Acronyms and abbreviations

Note: Abbreviations for amino acids are given in Appendix 1

5-HT	5-hydroxytryptamine (serotonin)	dATP	deoxyadenosine triphosphate
7-ACA	7-aminocephalosporinic acid	DCC	dicyclohexylcarbodiimide
6-APA	6-aminopenicillanic acid	dCTP	Deoxycytosine triphosphate
ACE	angiotensin-converting enzyme	DG	diacylglycerol
ACh	acetylcholine	dGTP	deoxyguanosine triphosphate
AChE	acetylcholinesterase	DHFR	dihydrofolate reductase
ACT	artemisinin combination therapy	DMAP	dimethylaminopyridine
ADAPT	antibody-directed abzyme prodrug therapy	DNA	deoxyribonucleic acid
ADEPT	antibody-directed enzyme prodrug therapy	DOR	delta opioid receptor
ADH	alcohol dehydrogenase	dsDNA	double-stranded DNA
ADME	absorption, distribution, metabolism, excretion	dsRNA	double-stranded RNA
ADP	adenosine diphosphate	dTMP	deoxythymidylate monophosphate
AIC	5-aminoimidazole-4-carboxamide	dTTP	deoxythymidylate triphosphate
AIDS	acquired immune deficiency syndrome	dUMP	deoxyuridylate monophosphate
AML	acute myeloid leukaemia	EC ₅₀	concentration of drug required to produce 50% of the maximum possible effect
AMP	adenosine 5'-monophosphate	E _s	Taft's steric factor
AT	angiotensin	EGF	epidermal growth factor
ATP	adenosine 5'-triphosphate	EGF-R	epidermal growth factor receptor
AUC	area under the curve	EMEA	European Agency for the Evaluation of Medicinal Products
cAMP	cyclic AMP	EPC	European Patent Convention
BuChE	butylcholinesterase	EPO	European Patent Office
CCK	cholecystokinin	FDA	US Food and Drug Administration
CDKs	cyclin-dependent kinases	FdUMP	fluorodeoxyuracil monophosphate
CETP	cholesteryl ester transfer protein	FGF	fibroblast growth factor
cGMP	cyclic GMP	FGF-R	fibroblast growth factor receptor
CHO cells	Chinese hamster ovarian cells	FH ₄	tetrahydrofolate
CKIs	cyclin-dependent kinase inhibitors	F	oral bioavailability
CLogP	calculated logarithm of the partition coefficient	F	inductive effect of an aromatic substituent in QSAR
CML	chronic myeloid leukaemia	F-SPE	fluorous solid phase extraction
CMV	cytomegalovirus	FLOG	flexible ligands orientated on grid
CNS	central nervous system	FPGS	folylpolyglutamate synthetase
CoA	coenzyme A	FPP	farnesyl diphosphate
CoMFA	comparative molecular field analysis	FT	farnesyl transferase
COMT	catechol O-methyltransferase	FTI	farnesyl transferase inhibitor
COX	cyclooxygenase	G-Protein	guanine nucleotide binding protein
CSD	Cambridge Structural Database	GABA	γ-aminobutyric acid
CYP	enzymes that constitute the cytochrome P450 family	GAP	GTPase activating protein
D-Receptor	dopamine receptor	GCP	Good Clinical Practice

xxii Acronyms and abbreviations

GDEPT	gene-directed enzyme prodrug therapy	IUPAC	International Union of Pure and Applied Chemistry
GDP	guanosine diphosphate	IV	intravenous
GEF	guanine nucleotide exchange factors	K_D	dissociation binding constant
GGTase	geranylgeranyltransferase	K_i	inhibition constant
GH	growth hormone	K_M	Michaelis constant
GIT	gastrointestinal tract	KOR	kappa opioid receptor
GLP	Good Laboratory Practice	LAAM	L- α -acetylmethadol
GMC	General Medical Council	LD ₅₀	lethal dose required to kill 50% of a test sample of animals
GMP	Good Manufacturing Practice	LDH	lactate dehydrogenase
GMP	guanosine monophosphate	LH	luteinizing hormone
GnRH	gonadotrophin-releasing hormone	LHRH	luteinizing hormone-releasing hormones
gp	glycoprotein	LipE	lipophilic efficiency
GTP	guanosine triphosphate	LogP	logarithm of the partition coefficient
h-PEPT	human intestinal proton-dependent oligopeptide transporter	LDL	low density lipoprotein
H-receptor	histamine receptor	LUMO	lowest unoccupied molecular orbital
HA	hemagglutinin	M-receptor	muscarinic receptor
HAART	highly active antiretroviral therapy	MAA	Marketing Authorization Application
HAMA	human anti-mouse antibodies	MAB	monoclonal antibody
HBA	hydrogen bond acceptor	MAO	monoamine oxidase
HBD	hydrogen bond donor	MAOI	monoamine oxidase inhibitor
HCV	hepatitis C virus	MAOS	microwave assisted organic synthesis
HDL	high density lipoprotein	MAP	mitogen-activated protein
HERG	human ether-a-go-go related gene	MAPK	mitogen-activated protein kinases
HIF	hypoxia-inducible factor	MCH-R	melanin-concentrating hormone receptor
HIV	human immunodeficiency virus	MDR	multidrug resistance
HMG-SCoA	3-hydroxy-3-methylglutaryl-coenzyme A	MDRTB	multidrug-resistant tuberculosis
HMGR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	MEP	molecular electrostatic potential
HOMO	highest occupied molecular orbital	miRNA	micro RNA
HPLC	high-performance liquid chromatography	miRNP	micro RNA protein
HPMA	N-(2-hydroxypropyl)methacrylamide	MMP	matrix metalloproteinase
HPT	human intestinal di-/tripeptide transporter	MMPI	matrix metalloproteinase inhibitor
HRV	human rhinoviruses	MOR	mu opioid receptor
HSV	herpes simplex virus	MR	molar refractivity
HTS	high-throughput screening	mRNA	messenger RNA
IC ₅₀	concentration of drug required to inhibit a target by 50%	MRSA	methicillin-resistant <i>Staphylococcus aureus</i>
IGF-1R	insulin growth factor 1 receptor	MTDD	multi-target drug discovery
IND	Investigational Exemption to a New Drug Application	mTRKI	multi-tyrosine receptor kinase inhibitor
IP ₃	inositol triphosphate	MWt	molecular weight
IPER	International Preliminary Examination Report	N-receptor	nicotinic receptor
IRB	Institutional Review Board	NA	neuraminidase or noradrenaline
ISR	International Search Report	NAD ⁺ /	nicotinamide adenine dinucleotide
ITC	isothermal titration calorimetry	NADH	
		NADP ⁺ /	nicotinamide adenine dinucleotide phosphate
		NADPH	
		NAG	N-acetylglucosamine
		NAM	N-acetylmuramic acid

NCE	new chemical entity	RMSD	root mean square distance
NDA	New Drug Application	rRNA	ribosomal RNA
NICE	National Institute for Health and Clinical Excellence	RNA	ribonucleic acid
NMDA	<i>N</i> -methyl-D-aspartate	<i>s</i>	standard error of estimate or standard deviation
NME	new molecular entity	SAR	structure–activity relationships
NMR	nuclear magnetic resonance	SCAL	safety-catch acid-labile linker
NNRTI	non-nucleoside reverse transcriptase inhibitor	SCF	stem cell factor
NO	nitric oxide	SCID	severe combined immunodeficiency disease
NOR	nociceptin opioid receptor	SKF	Smith-Kline and French
NOS	nitric oxide synthase	SNRI	selective noradrenaline reuptake inhibitors
NRTI	nucleoside reverse transcriptase inhibitor	siRNA	small inhibitory RNA
NSAID	non-steroidal anti-inflammatory drug	snRNA	small nuclear RNA
NVOC	nitroveratryloxycarbonyl	SOP	standard operating procedure
ORL1	opioid receptor-like receptor	SPA	scintillation proximity assay
<i>P</i>	partition coefficient	SPE	solid phase extraction
PABA	<i>p</i> -aminobenzoic acid	SPOS	solution phase organic synthesis
PBP	penicillin binding protein	SPR	surface plasmon resonance
PCP	phencyclidine, otherwise known as ‘angel dust’	ssDNA	single-stranded DNA
PCT	patent cooperation treaty	SSRI	selective serotonin reuptake inhibitor
PDB	protein data bank	ssRNA	single-stranded RNA
PDE	phosphodiesterase	TB	tuberculosis
PDGF	platelet-derived growth factor	TCA	tricyclic antidepressants
PDGF-R	platelet-derived growth factor receptor	TFA	trifluoroacetic acid
PDT	photodynamic therapy	TGF- α	transforming growth factor- α
PEG	polyethylene glycol	TGF- β	transforming growth factor- β
PGE	prostaglandin E	THF	tetrahydrofuran
PGF	prostaglandin F	TM	transmembrane
PIP ₂	phosphatidylinositol diphosphate	TNF	tumour necrosis factor
PI	protease inhibitor	TNF-R	tumour necrosis factor receptor
PKA	protein kinase A	TNT	trinitrotoluene
PKB	protein kinase B	TRAIL	TNF-related apoptosis-inducing ligand
PKC	protein kinase C	TRIPS	trade related aspects of intellectual property rights
PLC	phospholipase C	tRNA	transfer RNA
PLS	partial least squares	UTI	urinary tract infection
PPBI	protein–protein binding inhibitor	vdW	van der Waals
PPI	proton pump inhibitor	VEGF	vascular endothelial growth factor
Ppts	pyridinium 4-toluenesulfonate	VEGF-R	vascular endothelial growth factor receptor
QSAR	quantitative structure–activity relationships	VIP	vasoactive intestinal peptide
<i>r</i>	regression or correlation coefficient	VOC–Cl	vinylloxycarbonyl chloride
<i>R</i>	resonance effect of an aromatic substituent in QSAR	VRE	vancomycin-resistant enterococci
RES	reticuloendothelial system	VRSA	vancomycin-resistant <i>Staphylococci aureus</i>
RFC	reduced folate carrier	VZV	varicella-zoster viruses
RISC	RNA induced silencing complex	WHO	World Health Organization
		WTO	World Trade Organization

This page intentionally left blank

1

Drugs and drug targets: an overview

1.1 What is a drug?

The medicinal chemist attempts to design and synthesize a pharmaceutical agent that has a desired biological effect on the human body or some other living system. Such a compound could also be called a ‘drug’, but this is a word that many scientists dislike because society views the term with suspicion. With media headlines such as ‘Drugs Menace’ or ‘Drug Addiction Sweeps City Streets’, this is hardly surprising. However, it suggests that a distinction can be drawn between drugs that are used in medicine and drugs that are abused. Is this really true? Can we draw a neat line between ‘good drugs’ like penicillin and ‘bad drugs’ like heroin? If so, how do we define what is meant by a good or a bad drug in the first place? Where would we place a so-called social drug like cannabis in this divide? What about nicotine or alcohol?

The answers we get depend on who we ask. As far as the law is concerned, the dividing line is defined in black and white. As far as the party-going teenager is concerned, the law is an ass. As far as we are concerned, the questions are irrelevant. Trying to divide drugs into two categories—safe or unsafe, good or bad—is futile and could even be dangerous.

First, let us consider the so-called ‘good’ drugs used in medicines. How ‘good’ are they? If a drug is to be truly ‘good’ it would have to do what it is meant to do, have no toxic or unwanted side effects, and be easy to take.

How many drugs fit these criteria?

The short answer is ‘none’. There is no pharmaceutical compound on the market today that can completely satisfy all these conditions. Admittedly, some come quite close to the ideal. **Penicillin**, for example, has been one of the safest and most effective antibacterial agents ever discovered. Yet, it too has drawbacks. It cannot kill all known bacteria and, as the years have gone by, more and more bacterial strains have become resistant. Moreover, some individuals can experience severe allergic reactions to the compound.

Penicillin is a relatively safe drug, but there are some drugs that are distinctly dangerous. **Morphine** is one

such example. It is an excellent analgesic, yet there are serious side effects, such as tolerance, respiratory depression, and addiction. It can even kill if taken in excess.

Barbiturates are also known to be dangerous. At Pearl Harbor, American casualties were given barbiturates as general anaesthetics before surgery. However, because of a poor understanding about how barbiturates are stored in the body, many patients received sudden and fatal overdoses. In fact, it is thought that more casualties died at the hands of the anaesthetists at Pearl Harbor than died of their wounds.

To conclude, the ‘good’ drugs are not as perfect as one might think.

What about the ‘bad’ drugs then? Is there anything good that can be said about them? Surely there is nothing we can say in defence of the highly addictive drug known as heroin?

Well, let us look at the facts about heroin. It is one of the best painkillers we know. In fact, it was named heroin at the end of the nineteenth century because it was thought to be the ‘heroic’ drug that would banish pain for good. Heroin went on the market in 1898, but five years later the true nature of its addictive properties became evident and the drug was speedily withdrawn from general distribution. However, heroin is still used in medicine today—under strict control, of course. The drug is called **diamorphine** and it is the drug of choice for treating patients dying of cancer. Not only does diamorphine reduce pain to acceptable levels, it also produces a euphoric effect that helps to counter the depression faced by patients close to death. Can we really condemn a drug which does that as being all ‘bad’?

By now it should be evident that the division between good drugs and bad drugs is a woolly one and is not really relevant to our discussion of medicinal chemistry. All drugs have their good and bad points. Some have more good points than bad and vice versa, but, like people, they all have their own individual characteristics. So how are we to define a drug in general?

2 Chapter 1 Drugs and drug targets: an overview

One definition could be to classify drugs as 'compounds which interact with a biological system to produce a biological response'. This definition covers all the drugs we have discussed so far, but it goes further. There are chemicals that we take every day and which have a biological effect on us. What are these everyday drugs?

One is contained in all the cups of tea, coffee, and cocoa that we consume. All of these beverages contain the stimulant **caffeine**. Whenever you take a cup of coffee, you are a drug user. We could go further. Whenever you crave a cup of coffee, you are a drug addict. Even children are not immune. They get their caffeine 'shot' from Coke or Pepsi. Whether you like it or not, caffeine is a drug. When you take it, you experience a change of mood or feeling.

So too, if you are a worshipper of the 'nicotine stick'. The biological effect is different. In this case you crave sedation or a calming influence, and it is the **nicotine** in the cigarette smoke which induces that effect.

There can be little doubt that **alcohol** is a drug and, as such, causes society more problems than all other drugs put together. One only has to study road accident statistics to appreciate that fact. If alcohol was discovered today, it would probably be restricted in exactly the same way as **cocaine**. Considered in a purely scientific way, alcohol is a most unsatisfactory drug. As many will testify, it is notoriously difficult to judge the correct dose required to gain the beneficial effect of 'happiness' without drifting into the higher dose levels that produce unwanted side effects, such as staggering down the street. Alcohol is also unpredictable in its biological effects. Either happiness or depression may result, depending on the user's state of mind. On a more serious note, **addiction** and **tolerance** in certain individuals have ruined the lives of addicts and relatives alike.

Our definition of a drug can also be used to include other compounds which may not be obvious as drugs, for example poisons and toxins. They too interact with a biological system and produce a biological response—a bit extreme, perhaps, but a response all the same. The idea of poisons acting as drugs may not appear so strange if we consider penicillin. We have no problem in thinking of penicillin as a drug, but if we were to look closely at how penicillin works, then it is really a poison. It interacts with bacteria (the biological system) and kills them (the biological response). Fortunately for us, penicillin has no such effect on human cells.

Even those drugs which do not act as poisons have the potential to become poisons—usually if they are taken in excess. We have already seen this with morphine. At low doses it is a painkiller; at high doses, it is a poison which kills by the suppression of breathing. Therefore, it is important that we treat all medicines as potential poisons and treat them with respect.

There is a term used in medicinal chemistry known as the **therapeutic index**, which indicates how safe a particular drug is. The therapeutic index is a measure of the drug's beneficial effects at a low dose versus its harmful effects at a high dose. To be more precise, the therapeutic index compares the dose level required to produce toxic effects in 50% of patients with the dose level required to produce the maximum therapeutic effects in 50% of patients. A high therapeutic index means that there is a large safety margin between beneficial and toxic doses. The values for cannabis and alcohol are 1000 and 10, respectively, which might imply that cannabis is safer and more predictable than alcohol. Indeed, a cannabis preparation (**nabiximols**) has now been approved to relieve the symptoms of multiple sclerosis. However, this does not suddenly make cannabis safe. For example, the favourable therapeutic index of cannabis does not indicate its potential toxicity if it is taken over a long period of time (chronic use). For example, the various side effects of cannabis include panic attacks, paranoid delusions, and hallucinations. Clearly, the safety of drugs is a complex matter and it is not helped by media sensationalism.

If useful drugs can be poisons at high doses or over long periods of use, does the opposite hold true? Can a poison be a medicine at low doses? In certain cases, this is found to be so.

Arsenic is well known as a poison, but arsenic-derived compounds are used as antiprotozoal and anticancer agents. **Curare** is a deadly poison which was used by the native people of South America to tip their arrows such that a minor arrow wound would be fatal, yet compounds based on the **tubocurarine** structure (the active principle of curare) are used in surgical operations to relax muscles. Under proper control and in the correct dosage, a lethal poison may well have an important medical role. Alternatively, lethal poisons can be the starting point for the development of useful drugs. For example, **ACE inhibitors** are important cardiovascular drugs that were developed, in part, from the structure of a snake venom.

As our definition covers any chemical that interacts with any biological system, we could include all pesticides and herbicides as drugs. They interact with bacteria, fungi, and insects, kill them, and thus protect plants.

Even food can act like a drug. Junk foods and fizzy drinks have been blamed for causing hyperactivity in children. It is believed that junk foods have high concentrations of certain amino acids which can be converted in the body to neurotransmitters. These are chemicals that pass messages between nerves. If an excess of these chemical messengers should accumulate, then too many messages are transmitted in the brain, leading to the disruptive behaviour observed in susceptible individuals. Allergies due to food additives and preservatives are also well recorded.

Some foods even contain toxic chemicals. Broccoli, cabbage, and cauliflower all contain high levels of a chemical that can cause reproductive abnormalities in rats. Peanuts and maize sometimes contain fungal toxins, and it is thought that fungal toxins in food were responsible for the biblical plagues. Basil contains over 50 compounds that are potentially carcinogenic, and other herbs contain some of the most potent carcinogens known. Carcinogenic compounds have also been identified in radishes, brown mustard, apricots, cherries, and plums. Such unpalatable facts might put you off your dinner, but take comfort—these chemicals are present in such small quantities that the risk is insignificant. Therein lies a great truth, which was recognized as long ago as the fifteenth century when it was stated that ‘Everything is a poison, nothing is a poison. It is the dose that makes the poison.’

Almost anything taken in excess will be toxic. You can make yourself seriously ill by taking 100 aspirin tablets or a bottle of whisky or 9 kg of spinach. The choice is yours!

To conclude, drugs can be viewed as actual or potential poisons. An important principle is that of **selective toxicity**. Many drugs are effective because they are toxic to ‘problem cells’, but not normal cells. For example, antibacterial, antifungal, and antiprotozoal drugs are useful in medicine when they show a selective toxicity to microbial cells, rather than mammalian cells. Clinically effective anticancer agents show a selective toxicity for cancer cells over normal cells. Similarly, effective antiviral agents are toxic to viruses rather than normal cells.

Having discussed what drugs are, we shall now consider why, where, and how they act.

KEY POINTS

- Drugs are compounds that interact with a biological system to produce a biological response.
- No drug is totally safe. Drugs vary in the side effects they might have.
- The dose level of a compound determines whether it will act as a medicine or as a poison.
- The therapeutic index is a measure of a drug’s beneficial effect at a low dose versus its harmful effects at higher dose. A high therapeutic index indicates a large safety margin between beneficial and toxic doses.
- The principle of selective toxicity means that useful drugs show toxicity against foreign or abnormal cells but not against normal host cells.

1.2 Drug targets

Why should chemicals, some of which have remarkably simple structures, have such an important effect on such

a complicated and large structure as a human being? The answer lies in the way that the human body operates. If we could see inside our bodies to the molecular level, we would see a magnificent array of chemical reactions taking place, keeping the body healthy and functioning.

Drugs may be mere chemicals, but they are entering a world of chemical reactions with which they interact. Therefore, there should be nothing odd in the fact that they can have an effect. The surprising thing might be that they can have such *specific* effects. This is more a result of *where* they act in the body—the drug targets.

1.2.1 Cell structure

As life is made up of cells, then quite clearly drugs must act on cells. The structure of a typical mammalian cell is shown in Fig. 1.1. All cells in the human body contain a boundary wall called the **cell membrane** which encloses the contents of the cell—the **cytoplasm**. The cell membrane seen under the electron microscope consists of two identifiable layers, each of which is made up of an ordered row of phosphoglyceride molecules, such as **phosphatidylcholine (lecithin)** (Fig. 1.2). The outer layer of the membrane is made up of phosphatidylcholine, whereas the inner layer is made up of phosphatidylethanolamine, phosphatidylserine, and phosphatidylinositol. Each phosphoglyceride molecule consists of a small polar head-group and two long, hydrophobic (water-hating) chains.

In the cell membrane, the two layers of phospholipids are arranged such that the hydrophobic tails point towards each other and form a fatty, hydrophobic centre, while the ionic head-groups are placed at the inner and outer surfaces of the cell membrane (Fig. 1.3). This is a stable structure because the ionic, hydrophilic head-groups




FIGURE 1.1 A typical mammalian cell. Taken from Mann, J. (1992) *Murder, Magic, and Medicine*. Oxford University Press, with permission.




FIGURE 1.2 Phosphoglyceride structure.

interact with the aqueous media inside and outside the cell, whereas the hydrophobic tails maximize hydrophobic interactions with each other and are kept away from the aqueous environments. The overall result of this structure is to construct a fatty barrier between the cell's interior and its surroundings.

The membrane is not just made up of phospholipids, however. There are a large variety of proteins situated in the cell membrane (Fig. 1.3). Some proteins lie attached to the inner or the outer surface of the membrane. Others are embedded in the membrane with part of their structure exposed to one surface or both. The extent to which these proteins are embedded within the cell membrane structure depends on the types of amino acid present. Portions of protein that are embedded in the cell membrane have a large number of hydrophobic amino acids, whereas those portions that stick out from the surface have a large number of hydrophilic amino acids. Many surface proteins also have short chains of carbohydrates attached to them and are thus classed as **glycoproteins**.




FIGURE 1.3 Cell membrane. Taken from Mann, J. (1992) *Murder, Magic, and Medicine*. Oxford University Press, with permission.

These carbohydrate segments are important in cell–cell recognition (section 10.7).

Within the cytoplasm there are several structures, one of which is the **nucleus**. This acts as the 'control centre' for the cell. The nucleus contains the genetic code—the DNA—which acts as the blueprint for the construction of all the cell's proteins. There are many other structures within a cell, such as the mitochondria, the Golgi apparatus, and the endoplasmic reticulum, but it is not the purpose of this book to look at the structure and function of these organelles. Suffice it to say that different drugs act on molecular targets at different locations in the cell.

1.2.2 Drug targets at the molecular level

We shall now move to the molecular level, because it is here that we can truly appreciate how drugs work. The main molecular targets for drugs are proteins (mainly enzymes, receptors, and transport proteins) and nucleic acids (DNA and RNA). These are large molecules (**macromolecules**) that have molecular weights measured in the order of several thousand atomic mass units. They are much bigger than the typical drug, which has a molecular weight in the order of a few hundred atomic mass units.

The interaction of a drug with a macromolecular target involves a process known as binding. There is usually a specific area of the macromolecule where this takes place, known as the **binding site** (Fig. 1.4). Typically, this takes the form of a hollow or canyon on the surface of the macromolecule allowing the drug to sink into the body of the larger molecule. Some drugs react with the binding site and become permanently attached via a covalent bond that has a bond strength of 200–400 kJ mol⁻¹. However, most drugs interact through weaker forms of interaction known as **intermolecular bonds**. These include electrostatic or ionic bonds, hydrogen bonds, van der Waals interactions, dipole–dipole interactions, and hydrophobic interactions. (It is also possible for these interactions to take place *within* a molecule, in which case they are called **intramolecular bonds**; see for example protein structure, sections 2.2 and 2.3.) None of these bonds is as strong as the covalent bonds that make up the skeleton of a molecule, and so they can be formed and then broken again. This means that an equilibrium takes place between the drug being bound and unbound to its target. The binding forces are strong enough to hold the drug for a certain period of time to let it have an effect on the target, but weak enough to allow the drug to depart once it has done its job. The length of time the drug remains at its target will then depend on the number of intermolecular bonds involved in holding it there. Drugs that have a large number of interactions are likely




FIGURE 1.4 The equilibrium of a drug being bound and unbound to its target.

to remain bound longer than those that have only a few. The relative strength of the different intermolecular bonding forces is also an important factor. Functional groups present in the drug can be important in forming intermolecular bonds with the target binding site. If they do so, they are called **binding groups**. However, the carbon skeleton of the drug also plays an important role in binding the drug to its target through van der Waals interactions. As far as the target binding site is concerned, it too contains functional groups and carbon skeletons which can form intermolecular bonds with 'visiting' drugs. The specific regions where this takes place are known as **binding regions**. The study of how drugs interact with their targets through binding interactions and produce a pharmacological effect is known as **pharmacodynamics**. Let us now consider the types of intermolecular bond that are possible.

1.3 Intermolecular bonding forces

There are several types of intermolecular bonding interactions, which differ in their bond strengths. The number

and types of these interactions depend on the structure of the drug and the functional groups that are present (section 13.1 and Appendix 7). Thus, each drug may use one or more of the following interactions, but not necessarily all of them.

1.3.1 Electrostatic or ionic bonds

An ionic or electrostatic bond is the strongest of the intermolecular bonds ($20\text{--}40\text{ kJ mol}^{-1}$) and takes place between groups that have opposite charges, such as a carboxylate ion and an aminium ion (Fig. 1.5). The strength of the interaction is inversely proportional to the distance between the two charged atoms and it is also dependent on the nature of the environment, being stronger in hydrophobic environments than in polar environments. Usually, the binding sites of macromolecules are more hydrophobic in nature than the surface and so this enhances the effect of an ionic interaction. The drop-off in ionic bonding strength with separation is less than in other intermolecular interactions, so if an ionic interaction is possible, it is likely to be the most important initial interaction as the drug enters the binding site.




FIGURE 1.5 Electrostatic (ionic) interactions between a drug and the binding site.




FIGURE 1.6 Hydrogen bonding shown by a dashed line between a drug and a binding site (X, Y = oxygen or nitrogen; HBD = hydrogen bond donor, HBA = hydrogen bond acceptor).

1.3.2 Hydrogen bonds

A **hydrogen bond** can vary substantially in strength and normally takes place between an electron-rich heteroatom and an electron-deficient hydrogen (Fig. 1.6). The electron-rich heteroatom has to have a lone pair of electrons and is usually oxygen or nitrogen.

The electron-deficient hydrogen is usually linked by a covalent bond to an electronegative atom, such as oxygen or nitrogen. As the electronegative atom (X) has a greater attraction for electrons, the electron distribution in the covalent bond (X–H) is weighted towards the more electronegative atom and so the hydrogen gains its slight positive charge. The functional group containing this feature is known as a **hydrogen bond donor (HBD)** because it provides the hydrogen for the hydrogen bond. The functional group that provides the electron-rich atom to receive the hydrogen bond is known as the **hydrogen bond acceptor (HBA)**. Some functional groups can act both as hydrogen bond donors and hydrogen bond acceptors (e.g. OH, NH₂). When such a group is present in a binding site, it is possible that it might bind to one ligand as a hydrogen bond donor and to another as a hydrogen bond acceptor. This characteristic is given the term **hydrogen bond flip-flop**.

Hydrogen bonds have been viewed as a weak form of electrostatic interaction because the heteroatom is slightly negative and the hydrogen is slightly positive. However, there is more to hydrogen bonding than an attraction between partial charges. Unlike other intermolecular interactions, an interaction of orbitals takes place between the two molecules (Fig. 1.7). The orbital containing the lone pair of electrons on heteroatom (Y) interacts with the atomic orbitals normally involved in the covalent bond between X and H. This results in a

weak form of sigma (σ) bonding and has an important directional consequence that is not evident in electrostatic bonds. The optimum orientation is where the X–H bond points directly to the lone pair on Y such that the angle formed between X, H, and Y is 180°. This is observed in very strong hydrogen bonds. However, the angle can vary between 130° and 180° for moderately strong hydrogen bonds, and can be as low as 90° for weak hydrogen bonds. The lone pair orbital of Y also has a directional property depending on its hybridization. For example, the nitrogen of a pyridine ring is sp² hybridized and so the lone pair points directly away from the ring and in the same plane (Fig. 1.8). The best location for a hydrogen bond donor would be the region of space indicated in the figure.

The strength of a hydrogen bond can vary widely, but most hydrogen bonds in drug–target interactions are moderate in strength, varying from 16 to 60 kJ mol⁻¹—approximately 10 times less than a covalent bond. The bond distance reflects this; hydrogen bonds are typically 1.5–2.2 Å compared with 1.0–1.5 Å for a covalent bond. The strength of a hydrogen bond depends on how strong the hydrogen bond acceptor and the hydrogen bond donor are. A good hydrogen bond acceptor has to be electronegative and have a lone pair of electrons. Nitrogen and oxygen are the most common atoms involved as hydrogen bond acceptors in biological systems. Nitrogen has one lone pair of electrons and can act as an acceptor for one hydrogen bond; oxygen has two lone pairs of electrons and can act as an acceptor for two hydrogen bonds (Fig. 1.9).

Several drugs and macromolecular targets contain a sulphur atom, which is also electronegative. However, sulphur is a weak hydrogen bond acceptor because its lone pairs are in third-shell orbitals that are larger and more




FIGURE 1.7 Orbital overlap in a hydrogen bond.




FIGURE 1.8 Directional influence of hybridization on hydrogen bonding.




FIGURE 1.9 Oxygen and nitrogen acting as hydrogen bond acceptors (HBD = hydrogen bond donor, HBA = hydrogen bond acceptor).

diffuse. This means that the orbitals concerned interact less efficiently with the small 1s orbitals of hydrogen atoms.

Fluorine, which is present in several drugs, is more electronegative than either oxygen or nitrogen. It also has three lone pairs of electrons, which might suggest that it would make a good hydrogen bond acceptor. In fact, it is a weak hydrogen bond acceptor. It has been suggested

that fluorine is so electronegative that it clings on tightly to its lone pairs of electrons, making them incapable of hydrogen bond interactions. This is in contrast to fluoride ions which are very strong hydrogen bond acceptors.

Any feature that affects the electron density of the hydrogen bond acceptor is likely to affect its ability to act as a hydrogen bond acceptor; the greater the electron density of the heteroatom, the greater its strength as a hydrogen bond acceptor. For example, the oxygen of a negatively charged carboxylate ion is a stronger hydrogen bond acceptor than the oxygen of the uncharged carboxylic acid (Fig. 1.10). Phosphate ions can also act as good hydrogen bond acceptors. Most hydrogen bond acceptors present in drugs and binding sites are neutral functional groups, such as ethers, alcohols, phenols, amides, amines, and ketones. These groups will form moderately strong hydrogen bonds.

It has been proposed that the pi (π) systems present in alkynes and aromatic rings are regions of high electron density and can act as hydrogen bond acceptors. However, the electron density in these systems is diffuse and so the hydrogen bonding interaction is much weaker than those involving oxygen or nitrogen. As a result, aromatic rings and alkynes are only likely to be significant hydrogen bond acceptors if they interact with a strong hydrogen bond donor, such as an alkylammonium ion (NHR_3^+).

More subtle effects can influence whether an atom is a good hydrogen bond acceptor or not. For example, the nitrogen atom of an aliphatic tertiary amine is a better hydrogen bond acceptor than the nitrogen of an amide or an aniline (Fig. 1.11). In the latter cases, the lone pair




FIGURE 1.10 Relative strengths of hydrogen bond acceptors (HBAs).




FIGURE 1.11 Comparison of different nitrogen containing functional groups as hydrogen bond acceptors (HBAs).




FIGURE 1.12 Comparison of carbonyl oxygens as hydrogen bond acceptors.




FIGURE 1.13 Comparison of hydrogen bond donors (HBDs).

of the nitrogen can interact with neighbouring π systems to form various resonance structures. As a result, it is less likely to take part in a hydrogen bond.

Similarly, the ability of a carbonyl group to act as a hydrogen bond acceptor varies depending on the functional group involved (Fig. 1.12).

It has also been observed that an sp^3 hybridized oxygen atom linked to an sp^2 carbon atom rarely acts as an HBA. This includes the alkoxy oxygen of esters and the oxygen atom present in aromatic ethers or furans.

Good hydrogen bond donors contain an electron-deficient proton linked to oxygen or nitrogen. The more electron-deficient the proton, the better it will act as a hydrogen bond donor. For example, a proton attached to a positively charged nitrogen atom acts as a stronger hydrogen bond donor than the proton of a primary or secondary amine (Fig. 1.13). Because the nitrogen is charged, it has a greater pull on the electrons surrounding it, making attached protons even more electron-deficient.

1.3.3 Van der Waals interactions

Van der Waals interactions are very weak interactions that are typically 2–4 kJ mol⁻¹ in strength. They involve interactions between hydrophobic regions of different

molecules, such as aliphatic substituents or the overall carbon skeleton. The electronic distribution in neutral, non-polar regions is never totally even or symmetrical, and there are always transient areas of high and low electron densities leading to temporary dipoles. The dipoles in one molecule can induce dipoles in a neighbouring molecule, leading to weak interactions between the two molecules (Fig. 1.14). Thus, an area of high electron density on one molecule can have an attraction for an area of low electron density on another molecule. The strength of these interactions falls off rapidly the further the two molecules are apart, decreasing to the seventh power of the separation. Therefore, the drug has to be close to the target binding site before the interactions become important. Van der Waals interactions are also referred to as **London forces**. Although the interactions are individually weak, there may be many such interactions between a drug and its target, and so the overall contribution of van der Waals interactions is often crucial to binding. Hydrophobic forces are also important when the non-polar regions of molecules interact (section 1.3.6).

1.3.4 Dipole–dipole and ion–dipole interactions

Many molecules have a permanent dipole moment resulting from the different electronegativities of the atoms and functional groups present. For example, a ketone has a dipole moment due to the different electronegativities of the carbon and oxygen making up the carbonyl bond. The binding site also contains functional groups, so it is inevitable that it too will have various local dipole moments. It is possible for the dipole moments of the drug and the binding site to interact as a drug approaches, aligning the drug such that the dipole moments are parallel and in opposite directions (Fig. 1.15). If this positions the drug such that other intermolecular interactions can take place between it and the target, the alignment is beneficial to both binding and activity. If not, then binding and activity may be weakened. An example of such an effect can be found in antiulcer drugs (section 25.2.8.3). The strength of dipole–dipole interactions reduces with the




FIGURE 1.14 Van der Waals interactions between hydrophobic regions of a drug and a binding site.




FIGURE 1.15 Dipole–dipole interactions between a drug and a binding site.

cube of the distance between the two dipoles. This means that dipole–dipole interactions fall away more quickly with distance than electrostatic interactions, but less quickly than van der Waals interactions.

An ion–dipole interaction is where a charged or ionic group in one molecule interacts with a dipole in a second molecule (Fig. 1.16). This is stronger than a dipole–dipole interaction and falls off less rapidly with separation (decreasing relative to the square of the separation).

Interactions involving an induced dipole moment have been proposed. There is evidence that an aromatic ring can interact with an ionic group such as a quaternary ammonium ion. Such an interaction is feasible if

the positive charge of the quaternary ammonium group distorts the π electron cloud of the aromatic ring to produce a dipole moment where the face of the aromatic ring is electron-rich and the edges are electron-deficient (Fig. 1.17). This is also called a **cation- π interaction**. An important neurotransmitter called **acetylcholine** forms this type of interaction with its binding site (section 22.5).

1.3.5 Repulsive interactions

So far we have concentrated on attractive forces, which increase in strength the closer the molecules approach each other. Repulsive interactions are also important.




FIGURE 1.16 Ion–dipole interactions between a drug and a binding site.




FIGURE 1.17 Induced dipole interaction between an alkylammonium ion and an aromatic ring.




FIGURE 1.18 Desolvation of a drug and its target binding site prior to binding.




FIGURE 1.19 Hydrophobic interactions.

Otherwise, there would be nothing to stop molecules trying to merge with each other! If molecules come too close, their molecular orbitals start to overlap and this results in repulsion. Other forms of repulsion are related to the types of groups present in both molecules. For example, two charged groups of identical charge are repelled.

1.3.6 The role of water and hydrophobic interactions

A crucial feature that is often overlooked when considering the interaction of a drug with its target is the role of water. The macromolecular targets in the body exist in an aqueous environment and the drug has to travel through that environment in order to reach its target; therefore, both the drug and the macromolecule are solvated with water molecules before they meet each other. The water molecules surrounding the drug and the target binding site have to be stripped away before the interactions described above can take place (Fig. 1.18). This requires energy and if the energy required to desolvate both the drug and the binding site is greater than the stabilization energy gained by the binding interactions, then the drug may be ineffective. In certain cases, it has even proved beneficial to remove a polar binding group from a drug in order to lower its energy of desolvation. For example, this was carried out during the development of the antiviral drug **ritonavir** (section 20.7.4.4).

Sometimes polar groups are added to a drug to increase its water solubility. If this is the case, it is important that such groups are positioned in such a way that they protrude from the binding site when the drug binds; in other words, they are solvent-accessible or solvent-exposed. In this way, the water that solvates this highly polar group does not have to be stripped away and there is no energy penalty when the drug binds to its target (see section 21.6.2.1 and Case study 5).

It is not possible for water to solvate the non-polar or hydrophobic regions of a drug or its target binding site. Instead, the surrounding water molecules form stronger-than-usual interactions with each other, resulting in a more ordered layer of water next to the non-polar surface. This represents a negative entropy due to the increase in order. When the hydrophobic region of a drug interacts with a hydrophobic region of a binding site, these water molecules are freed and become less ordered (Fig. 1.19). This leads to an increase in entropy and a gain in binding energy.* The interactions involved are small at 0.1–0.2 kJ mol⁻¹ for each Å² of hydrophobic surface, but overall they can be substantial. Sometimes, a hydrophobic region in the drug may not be sufficiently close to a hydrophobic

* The free energy gained by binding (ΔG) is related to the change in entropy (ΔS) by the equation $\Delta G = \Delta H - T\Delta S$. If entropy increases, ΔS is positive, which makes ΔG more negative. The more negative ΔG is, the more likely binding will take place.

region in the binding site and water may be trapped between the two surfaces. The entropy increase is not so substantial in that case and there is a benefit in designing a better drug that fits more snugly.

1.4 Pharmacokinetic issues and medicines

Pharmacodynamics is the study of how a drug binds to its target binding site and produces a pharmacological effect. However, a drug capable of binding to a particular target is not necessarily going to be useful as a clinical agent or medicine. For that to be the case, the drug not only has to bind to its target, it has to reach it in the first place. For an orally administered drug, that involves a long journey with many hazards to be overcome. The drug has to survive stomach acids then digestive enzymes in the intestine. It has to be absorbed from the gut into the blood supply and then it has to survive the liver where enzymes try to destroy it (drug metabolism). It has to be distributed round the body and not get mopped up by fat tissue. It should not be excreted too rapidly or else frequent doses will be required to maintain activity. However, it should not be excreted too slowly or its effects could linger on longer than required. The study of how a drug is absorbed, distributed, metabolized, and excreted (known as ADME in the pharmaceutical industry) is called **pharmacokinetics**. Pharmacokinetics has sometimes been described as ‘what the body does to the drug’ as opposed to pharmacodynamics—‘what the drug does to the body’.

There are many ways in which medicinal chemists can design a drug to improve its pharmacokinetic properties, but the method by which the drug is formulated and administered is just as important. Medicines are not just composed of the active pharmaceutical agent. For example, a pill contains a whole range of chemicals that are present to give structure and stability to the pill, and also to aid the delivery and breakdown of the pill at the desired part of the gastrointestinal tract.

KEY POINTS

- Drugs act on molecular targets located in the cell membrane of cells or within the cells themselves.
- Drug targets are macromolecules that have a binding site into which the drug fits and binds.
- Most drugs bind to their targets by means of intermolecular bonds.
- Pharmacodynamics is the study of how drugs interact with their targets and produce a pharmacological effect.
- Electrostatic or ionic interactions occur between groups of opposite charge.
- Hydrogen bonds occur between an electron-rich heteroatom and an electron-deficient hydrogen.
- The functional group providing the hydrogen for a hydrogen bond is called the hydrogen bond donor. The functional group that interacts with the hydrogen in a hydrogen bond is called the hydrogen bond acceptor.
- Van der Waals interactions take place between non-polar regions of molecules and are caused by transient dipole–dipole interactions.
- Ion–dipole and dipole–dipole interactions are a weak form of electrostatic interaction.
- Hydrophobic interactions involve the displacement of ordered layers of water molecules which surround hydrophobic regions of molecules. The resulting increase in entropy contributes to the overall binding energy.
- Polar groups have to be desolvated before intermolecular interactions take place. This results in an energy penalty.
- The pharmacokinetics of a drug relate to its absorption, distribution, metabolism, and excretion in the body.

1.5 Classification of drugs

There are four main ways in which drugs might be classified or grouped.

By pharmacological effect Drugs can be classified depending on the biological or pharmacological effect that they have, for example analgesics, antipsychotics, antihypertensives, anti-asthmatics, and antibiotics. This is useful if one wishes to know the full scope of drugs available for a certain ailment, but it means that the drugs included are numerous and highly varied in structure. This is because there are a large variety of targets at which drugs could act in order to produce the desired effect. It is therefore not possible to compare different painkillers and expect them to look alike or to have some common mechanism of action.

The chapters on antibacterial, antiviral, anticancer, and anti-ulcer drugs (Chapters 19–21 and 25) illustrate the variety of drug structures and mechanisms of action that are possible when drugs are classified according to their pharmacological effect.

By chemical structure Many drugs which have a common skeleton are grouped together, for example penicillins, barbiturates, opiates, steroids, and catecholamines. In some cases, this is a useful classification as the biological activity and mechanism of action is the same for the structures involved, for example the antibiotic activity of penicillins. However, not all compounds with similar chemical structures have the same biological action. For example, steroids share a similar tetracyclic structure, but they have very different effects in the body. In this text, various groups of structurally related drugs are

discussed, for example penicillins, cephalosporins, sulphonamides, opioids, and glucocorticoids (sections 19.4 and 19.5, Chapter 24 and Case study 6). These are examples of compounds with a similar structure and similar mechanism of action. However, there are exceptions. Most sulphonamides are used as antibacterial agents, but there are a few which have totally different medical applications.

By target system Drugs can be classified according to whether they affect a certain target system in the body. An example of a target system is where a neurotransmitter is synthesized, released from its neuron, interacts with a protein target, and is either metabolized or reabsorbed into the neuron. This classification is a bit more specific than classifying drugs by their overall pharmacological effect. However, there are still several different targets with which drugs could interact in order to interfere with the system and so the drugs included in this category are likely to be quite varied in structure because of the different mechanisms of action that are involved. In Chapters 22 and 23 we look at drugs that act on target systems—the cholinergic and the adrenergic system respectively.

By target molecule Some drugs are classified according to the molecular target with which they interact. For example, anticholinesterases (sections 22.12–22.15) are drugs which act by inhibiting the enzyme **acetylcholinesterase**. This is a more specific classification as we have now identified the precise target at which the drugs act. In this situation we might expect some structural similarity between the agents involved and a common mechanism of action, although this is not an inviolable assumption. However, it is easy to lose the wood for the trees and to lose sight of why it is useful to have drugs which switch off a particular enzyme or receptor. For example, it is not intuitively obvious why an anticholinesterase agent could be useful in treating Alzheimer's disease or glaucoma.

1.6 Naming of drugs and medicines

The vast majority of chemicals that are synthesized in medicinal chemistry research never make it to the market place and it would be impractical to name them all. Instead, research groups label them with a code which usually consists of letters and numbers. The letters are specific to the research group undertaking the work and the number is specific for the compound. Thus, Ro31-8959, ABT-538, and MK-639 were compounds prepared by Roche, Abbott, and Merck pharmaceuticals respectively. If the compounds concerned show promise as therapeutic drugs they are taken into development and named. For example, the above compounds showed promise as anti-HIV drugs and were named **saquinavir**, **ritonavir**, and **indinavir**

respectively. Finally, if the drugs prove successful and are marketed as medicines, they are given a proprietary, brand, or trade name, which only the company can use. For example, the above compounds were marketed as **Fortovase®**, **Norvir®** and **Crixivan®** respectively (note that brand names always start with a capital letter and have the symbol R or TM to indicate that they are registered brand names). The proprietary names are also specific for the preparation or formulation of the drug. For example, Fortovase® (or Fortovase™) is a preparation containing 200 mg of saquinavir in a gel-filled, beige-coloured capsule. If the formulation is changed, then a different name is used. For example, Roche sell a different preparation of saquinavir called **Invirase®** which consists of a brown/green capsule containing 200 mg of saquinavir as the mesylate salt. When a drug's patent has expired, it is possible for any pharmaceutical company to produce and sell that drug as a generic medicine. However, they are not allowed to use the trade name used by the company that originally invented it. European law requires that generic medicines are given a **recommended International Non-proprietary Name** (rINN), which is usually identical to the name of the drug. In the UK, such drugs were given a **British Approved Name** (BAN), but these have now been modified to fall in line with rINNs.

As the naming of drugs is progressive, early research articles in the literature may only use the original letter/number code as the name of the drug had not been allocated at the time of publication.


Throughout this text, the names of the active constituents are used rather than the trade names, although the trade name may be indicated if it is particularly well known. For example, it is indicated that **sildenafil** is **Viagra®** and that **paclitaxel** is **Taxol®**. If you wish to find out the trade name for a particular drug, these are listed in Appendix 6. If you wish to 'go the other way', Appendix 7 contains trade names and directs you to the relevant compound name. Only those drugs covered in the text are included and if you cannot find the drug you are looking for, you should refer to other textbooks or formularies such as the British National Formulary (see 'General further reading').

KEY POINTS


- Drugs can be classified by their pharmacological effect, their chemical structure, their effect on a target system, or their effect on a target structure.
- Clinically useful drugs have a trade (or brand) name, as well as a recommended international non-proprietary name.
- Most structures produced during the development of a new drug are not considered for the clinic. They are identified by simple codes that are specific to each research group.

QUESTIONS


- The hormone adrenaline interacts with proteins located on the surface of cells and does not cross the cell membrane. However, larger steroid molecules, such as estrone, cross cell membranes and interact with proteins located in the cell nucleus. Why is a large steroid molecule able to cross the cell membrane when a smaller molecule such as adrenaline cannot?
- Valinomycin is an antibiotic which is able to transport ions across cell membranes and disrupt the ionic balance of the cell. Find out the structure of valinomycin and explain why it is able to carry out this task.
- Archaea are microorganisms that can survive in extreme environments, such as high temperature, low pH, or high salt concentrations. It is observed that the cell membrane phospholipids in these organisms (see Structure I below) are markedly different from those in eukaryotic cell membranes. What differences are present and what function might they serve?



Adrenaline




Estrone



Structure I

- Teicoplanin is an antibiotic which 'caps' the building blocks used in the construction of the bacterial cell wall such that they cannot be linked up. The cell wall is a barrier surrounding the bacterial cell membrane and the building blocks are anchored to the outside of this cell membrane prior to their incorporation into the cell wall. Teicoplanin contains a very long alkyl substituent which plays no role in the capping mechanism. However, if this substituent is absent, activity drops. What role do you think this alkyl substituent might serve?
- The Ras protein is an important protein in signalling processes within the cell. It exists freely in the cell cytoplasm, but must become anchored to the inner surface of the cell membrane in order to carry out its function. What kind of modification to the protein might take place to allow this to happen?
- Cholesterol is an important constituent of eukaryotic cell membranes and affects the fluidity of the membrane. Consider the structure of cholesterol (shown below) and suggest how it might be orientated in the membrane.
- Most unsaturated alkyl chains in phospholipids are *cis* rather than *trans*. Consider the *cis*-unsaturated alkyl chain in the phospholipid shown in Fig. 1.2. Redraw this chain to give a better representation of its shape and compare it with the shape of its *trans*-isomer. What conclusions can you make regarding the packing of such chains in the cell membrane and the effect on membrane fluidity?
- The relative strength of carbonyl oxygens as hydrogen bond acceptors is shown in Fig. 1.12. Suggest why the order is as shown.
- Consider the structures of adrenaline, estrone, and cholesterol and suggest what kind of intermolecular interactions are possible for these molecules and where they occur.
- Using the index and Appendix 6, identify the structures and trade names for the following drugs—amoxicillin, ranitidine, gefitinib, and atracurium.



Cholesterol

FURTHER READING

- Hansch, C., Sammes, P. G., and Taylor, J. B. (eds) (1990) Classification of drugs. *Comprehensive Medicinal Chemistry*, Vol. 1, Chapter 3.1. Pergamon Press, ISBN 0-08-037057-8.
- Howard, J. A. K., Hoy, V. J., O'Hagan, D., and Smith, G. T. (1996) How good is fluorine as a hydrogen bond acceptor? *Tetrahedron* **52**, 12613–12622.
- Jeffrey, G. A. (1991) *Hydrogen Bonding in Biological Structures*. Springer-Verlag, London.
- Kubinyi, H. (2001) Hydrogen bonding: The last mystery in drug design? In: Testa, B. (ed.) *Pharmacokinetic Optimisation in Drug Research*. Wiley, 513–24.
- Mann, J. (1992) *Murder, Magic, and Medicine*, Chapter 1. Oxford University Press, Oxford.
- Meyer, E. G., Botos, I., Scapozza, L., and Zhang, D. (1995) Backward binding and other structural surprises. *Perspectives in Drug Discovery and Design* **3**, 168–195.
- Page, C., Curtis, M., Sutter, M., Walker, M., and Hoffman, B. (2002) Drug names and drug classification systems. *Integrated Pharmacology*, 2nd edn, Chapter 2. Mosby, St Louis, MO.

Titles for general further reading are listed on p.763.